*2 Before W ILLIAM P RYOR , Chief Judge, W ILSON , J ORDAN , R OSENBAUM , J ILL P RYOR , N EWSOM , B RANCH , G RANT , L UCK , L AGOA , and B RASHER , Circuit Judges. ∗
BY THE COURT:
A petition for rehearing having been filed and a mem- ber of this Court in active service having requested a poll on whether this case should be reheard by the Court sitting en banc, and a majority of the judges in active service on this Court having voted against granting rehearing en banc, it is ORDERED that this case will not be reheard en banc.
∗ Judge Nancy Abudu recused herself and did not participate in the en banc poll.
W ILLIAM P RYOR , Chief Judge, respecting the denial of rehearing en banc:
I agree with the decision not to rehear this appeal en banc and write only to respond to a dissenting opinion. Our respected colleague argues that the “complex[]” doctrine of substantive due process is “hard,” Jordan Dissent at 1, but the difficulty is inevitable. The doctrine of substantive due process does violence to the text of the Constitution, enjoys no historical pedigree, and offers judges little more than shifting and unilluminating standards with which to protect unenumerated rights. Unmoored from text and history, the drift of the doctrine—“neither linear nor consistent,” id. at 20— is predictable. So too is its patchy legacy: unelected judges with life tenure enjoin enforcement of laws enacted by elected representa- tives following regular procedures, all in the name of fundamental rights that the Constitution never names but allegedly secures. In the absence of clear guidance from the Supreme Court, we should hesitate to expand the reach of this f lawed doctrine. And our Court wisely declines to do so here.
As John Hart Ely famously put it, the phrase “substantive
due process” is a “contradiction in terms,” like “‘green pastel red-
ness.’” J OHN H ART E LY , D EMOCRACY AND D ISTRUST 18 (1980). The
Fifth and Fourteenth Amendments prohibit the federal and state
governments from depriving any person of life, liberty, or property
“without due process of law.” That constitutional guarantee is
about legal procedures, not the substance of laws. For that reason,
the Supreme Court has declared—unanimously—that the
*4
“language” of the Due Process Clauses does not “suggest[],” let
alone support, the “substantive content” that courts often have
poured into them.
Regents of the Univ. of Mich. v. Ewing
,
In addition to incorporating against the States most of the
protections that the Bill of Rights guarantees against the federal
government, the doctrine bars state infringement of “fundamental
rights that are not mentioned anywhere in the Constitution.”
Dobbs
v. Jackson Women’s Health Org.
,
The doctrine of substantive due process has “long been con-
troversial,”
Dobbs
,
Some scholars argue that the phrase “due process of law” was a “legal term of art with substantive content” when the Four- teenth Amendment was ratified in 1868. See, e.g. , Williams, supra , at 496 (presenting the argument). But that argument is “hardly air- tight,” id. , and “[n]o evidence” establishes that the word “process” “meant something different” in 1868, set aside 1791, from what it does now, see E LY , supra , at 18. To trained observers no less than the ordinary man, the choice of the phrase “due process of law” to af- ford constitutional protection to substantive rights would have seemed “very odd.” Chapman & McConnell, supra , at 1725.
A constitutional doctrine that lacks foundation in text or his-
tory must draw its content from another source, and substantive
due process has offered judges little more than “scarce and open-
ended” platitudes.
Collins v. City of Harker Heights
,
Unconstrained power tempts usurpation. The history of
substantive due process bears out that plain truth. In many deci-
sions, the Supreme Court has stated that the approach to constitu-
tional decision-making typified by
Lochner v. New York
,
Because the doctrine can empower judges to “usurp” au-
thority that the Constitution leaves to elected representatives,
see
Dobbs
,
Sometimes courts have defined the asserted unenumerated
right at a specific level. In
Reno
, for example, the Supreme Court
rejected the proposed general description of the right at issue—
“freedom from physical restraint”—and defined the right instead
more specifically as the “right of a child who has no available par-
ent, close relative, or legal guardian, and for whom the government
is responsible, to be placed in the custody of a willing-and-able pri-
vate custodian rather than of a government-operated or govern-
ment-selected child-care institution.”
Id.
(quotation marks omit-
ted). And in
Doe v. Moore
, we rejected a “broad framing” of the
rights at issue—including the rights “to family association” and to
“be free of threats to their persons and members of their immedi-
ate families”—for a more “careful” description: the “right of a per-
son, convicted of ‘sexual offenses,’ to refuse subsequent registra-
tion of his or her personal information with Florida law enforce-
ment and [to] prevent publication of this information on Florida’s
Sexual Offender/Predator website.”
To be sure, the
Glucksberg
test has proved occasional. In
Law-
rence v. Texas
, the Supreme Court endorsed the uncircumscribed
view that the Due Process Clause protected a “liberty of the person
both in its spatial and in its more transcendent dimensions.” 539
U.S. 558, 562 (2003). And in
Obergefell
, the Court set aside the
Glucks-
berg
test and defined the right to marry in a more “comprehensive
sense.”
Yet what judicial creativity gives, a measure of judicial re- straint can take away. For example, Dobbs did not mention the al- ternative Obergefell method. So I agree with our dissenting col- league that binding precedents like these are “not . . . reconcilable” on the key question of how narrowly to define the liberty interest. Jordan Dissent at 20.
This inconsistency is unsurprising. It is inevitable. The “con- troversial nature” of the doctrine of substantive due process—its lack of footing in text or history and the absence of consistent and meaningful legal standards to guide judicial analysis— make the caselaw “contradictory” and “imprecise.” Tymkovich et al., supra , at 1963.
With good reason, the Supreme Court has long counseled
“reluctan[ce] to expand the concept of substantive due process.”
Collins
,
L AGOA , Circuit Judge, Concurring in the denial of rehearing en banc:
Sydney Wright took large doses of cross-sex hormones for a year. In Wright’s words, her grandfather “saved [her] life” when he persuaded her to stop. As a teenager, Wright’s father kicked her out of the house after he learned that she was attracted to women, and Wright began questioning if she “was really a man” because she “was attracted to girls.” Wright saw a counselor who recom- mended that she begin taking testosterone and undergo a double mastectomy. The counselor never explored the negative effects of Wright’s relationship with her parents or the years of sexual mo- lestation that she endured as a child. Wright started testosterone injections after a ten-minute appointment with a physician who told her to learn “on YouTube” how to “give [herself] the shots.”
Testosterone caused Wright’s voice to deepen, perma- nently. She also gained fifty pounds and became pre-diabetic. After a year, her blood thickened, her red-blood-cell count increased, and she developed a blood disorder that could lead to heart attack and stroke. She also began experiencing excruciating abdominal pain, which she continues to suffer from. One day, her grandfather— who Wright describes as “the most important man in [her] life”— had a “down-to-earth” talk with her. With “tears in his eyes,” he expressed concern about her treatment and asked her to take a three-year break to reevaluate her decision. According to Wright, her grandfather was “worried about [her] health,” and he “never cared how [she] looked.” Wright agreed to take a break, and on *12 further reflection, realized that she needed counseling, not hor- mone medications. Wright still suffers negative side effects from cross-sex hormones, including digestive problems, tachycardia, and an increased red-blood-cell count. Her gynecologist also told her that she may never be able to have children.
The record contains many stories of others who were irre-
versibly harmed by similar medications.
[1]
The Alabama Legislature
decided to respond through Alabama’s Vulnerable Child Compas-
sion and Protection (“Act”). In relevant part, section 4(a)(1)–(3) of
the Act provides that “no person shall” prescribe or administer pu-
berty blocking medication or cross-sex hormones to a minor “for
the purpose of attempting to alter the appearance of or affirm the
minor’s perception of his or her gender or sex, if that appearance
or perception is inconsistent with the minor’s sex.” A federal dis-
trict court preliminarily enjoined enforcement of part of the Act
under the Due Process Clause and the Equal Protection Clause of
the Fourteenth Amendment. But we reversed. Now, a majority
of the active judges on this Court have correctly determined not to
*13
rehear this case en banc. The Act, “like other health and welfare
laws, is entitled to a ‘strong presumption of validity.’”
Dobbs v. Jack-
son Women’s Health Org.
,
Judge Rosenbaum’s dissent characterizes the panel opinion
as holding that parents do not have a constitutional right to access
“life-saving medical care” for their children. Rosenbaum Dis. Op.
at 4;
see also
Jordan Dis. Op. at 22 (describing the asserted right as
“the right of parents to obtain medically-approved treatment for
their children”). But frankly, whether puberty blockers and cross-
sex hormones qualify as “life-saving” treatment—or even “medical
care”—is a policy question informed by scientific, philosophical,
and moral considerations. Neither an unelected district judge nor
unelected circuit judges should resolve that debate for the State of
Alabama.
See Kadel v. Folwell
,
Indeed, “when a legislature ‘undertakes to act in areas
fraught with medical and scientific uncertainties, legislative options
must be especially broad and courts should be cautious not to re-
write legislation.’”
Kansas v. Hendricks
,
For example, in April 2024, Dr. Hillary Cass—the chair of a policy group commissioned by England’s National Health Service (“NHS”)—published the results of her four-year review of the use of puberty blockers and cross-sex hormones on minors. [2] Cass found no evidence that puberty blockers improve gender dyspho- ria and no evidence that cross-sex hormones reduce suicide risk for children suffering from gender dysphoria. See The Cass Review, supra n.2, at 179, 186, 195. Cass also documented the extensive risks associated with puberty blockers. See, e.g. , id. at 177–78. In conjunction with the Cass Review, NHS announced “that there is not enough evidence to support the safety or clinical effectiveness of [puberty suppressing hormones] to make the treatment rou- tinely available at this time.” [3] And, on May 29, 2024, the United Kingdom’s Secretary of State for Health and Social Care and North- ern Ireland’s Minister for Health issued a temporary emergency or- der that “prohibits”—with limited exceptions—puberty blockers *15 for people under the age of 18. See TransActual CIC v. Sec’y of State for Health and Social Care [2024] EWHC 1936 (Admin), ¶¶ 2, 142–48. On July 29, 2024, the UK’s High Court dismissed a legal challenge to the emergency order, citing the Cass Review as “powerful scien- tific evidence in support of restrictions on the supply of puberty blockers on the grounds that they were potentially harmful.” See id. ¶¶ 210, 257.
Also, in March 2024, a whistleblower leaked documents and recordings impugning the credibility of the World Professional As- sociation for Transgender Health (WPATH), [4] which promulgates the “Standards of Care” that the district court relied on in its order. Eknes-Tucker v. Marshall (“ Eknes-Tucker I ”), 603 F. Supp. 3d 1131, 1138–39 (M.D. Ala. 2022). The leaked documents suggest that WPATH officials are aware of the risks of cross-sex hormones and other procedures yet are mischaracterizing and ignoring infor- mation about those risks. See, e.g. , infra at 47–49. Again, I highlight these developments only to demonstrate the ill-suitedness of this area for judicial intervention.
The propriety of the medications at issue is a quintessential
legislative question, not a constitutional one. Judges Jordan and
Rosenbaum would have this Court end the debate by judicially
fencing off these questions from state legislatures. But our
*16
experience with the intersection of the Constitution and these
types of issues suggests that this is a misguided effort.
See Roe v.
Wade
,
I. FACTUAL BACKGROUND AND PROCEDURAL
HISTORY
The panel opinion provides a thorough summary of the fac-
tual background and procedural history.
See Eknes-Tucker v. Gover-
nor of Alabama
(“
Eknes-Tucker II
”),
A. The Act The Alabama Legislature passed the Act on April 7, 2022, and Governor Ivey signed it the next day. Section 3(1) incorporates the definition of “minor” found in another part of the code, which is a “person who is under 19 years of age.” Ala. Code § 43-8-1(18). And section 3(3) defines “sex” to mean “[t]he biological state of be- ing male or female, based on the individual’s sex organs, *17 chromosomes, and endogenous hormone profiles.” Section 4(a) then states, in part, that “no person shall engage in or cause” the prescription or administration of (1) “puberty blocking medication to stop or delay normal puberty,” (2) “supraphysiologic [5] doses of testosterone or other androgens to females,” or (3) “supraphysio- logic doses of estrogen to males,” “for the purpose of attempting to alter the appearance of or affirm the minor’s perception of his or her gender or sex, if that appearance or perception is inconsistent with the minor’s sex.” [6] Section 4(b), however, provides an excep- tion if “a procedure [is] undertaken to treat a minor born with a medically verifiable disorder of sex development,” and includes some examples of such disorders. [7]
B. Procedural History Shortly after the Governor signed the Act, the Plaintiffs— including transgender minors (the “Minor Plaintiffs”) and their par- ents (the “Parent Plaintiffs”)—sued several Alabama state officials (collectively, “Alabama”). Relevant to this appeal, the Plaintiffs al- leged that the Act violated the Due Process Clause of the Four- teenth Amendment by depriving the Parent Plaintiffs of their right to direct the upbringing of their children, and alleged that the Act violated the Equal Protection Clause by discriminating against the Minor Plaintiffs on account of their sex and transgender status.
The Plaintiffs then moved for a preliminary injunction.
[8]
Af-
ter a three-day hearing—at which the district court heard evidence
from both sides about the efficacy of the treatments proscribed by
the Act,
see Eknes-Tucker II
,
[8] The United States moved to intervene on behalf of the Plaintiffs under Fed-
eral Rule of Civil Procedure 24 and filed its own motion to enjoin enforcement
of the Act on equal-protection grounds. The district court granted interven-
tion and the United States’s motion for injunctive relief to the same extent it
granted the Plaintiffs’ motion.
Eknes-Tucker I
,
II. ANALYSIS
On appeal, the panel unanimously concluded that the dis-
trict court abused its discretion by preliminarily enjoining Alabama
officials from enforcing section 4(a)(1)–(3) of the Act.
Eknes-Tucker
II
,
Some of my dissenting colleagues interpret the Fourteenth Amendment differently. I respectfully disagree. Below, I first ex- plain why the panel’s understanding of the Fourteenth Amend- ment is consistent with text, history, tradition, and existing prece- dent. I then explain why Alabama’s decision is a rational exercise of its police power.
A. Substantive Due Process
The Due Process Clause of the Fourteenth Amendment pro-
vides that no State shall “deprive any person of life, liberty, or prop-
erty, without due process of law.” U.S. Const. amend. XIV, § 1.
Because this Clause makes no express mention of a parent’s right
to access cross-sex hormones and puberty blockers on behalf of a
child, the Parent Plaintiffs “must show that the right is somehow
implicit in the constitutional text.”
Dobbs
,
“The most familiar office of [the Due Process] Clause is to
provide a guarantee of fair procedure in connection with any dep-
rivation of life, liberty, or property by a State.”
Collins v. City of
Harker Heights
,
Out of this cautious approach grew the requirement that a substantive-due-process analysis “must begin with a careful de- scription of the asserted right.” Reno v. Flores , 507 U.S. 292, 302 (1993). Heeding this directive, the panel opinion’s description of the right claimed here came directly from the district court, which concluded that the Parent Plaintiffs likely have a “fundamental right to treat their children with transitioning medications subject to medically accepted standards.” Eknes-Tucker I , 603 F. Supp. 3d at 1144.
The dissents take issue with this framing. Judge Jordan de- scribes our analysis as “too simple” and says that we “ignore[] many Supreme Court cases that define fundamental rights at a much more general level without requiring established and precise his- torical pedigrees.” Jordan Dis. Op. at 2. He “cite[s] with confidence to the dissent of Justice Stevens in McDonald ,” id. at 7, where Justice Stevens suggested that courts need not “define the asserted right at the most specific level, thereby sapping it of a universal valence and moral force it might otherwise have,” McDonald v. City of Chicago , *22 561 U.S. 742, 882 (2010) (Stevens, J., dissenting). Judge Jordan would instead define the right as a parent’s right “to obtain medi- cally-approved treatment for their children.” Jordan Dis. Op. at 22.
Judge Rosenbaum defines the right at stake as “parents’ fun- damental right to direct that their child receive well-established, evidence-based, non-experimental medical treatment, subject to medically accepted standards and a physician’s independent exam- ination and medical judgment.” Rosenbaum Dis. Op. at 1. Her opinion also faults our panel for “hyper-narrowly describ[ing] the asserted right.” Id. at 31.
And Judge Wilson argues that en banc review is justified be- cause of Judges Jordan and Rosenbaum’s disagreement with our framing of the supposed right at stake, as well as the fact that the district court also framed the right at a higher level of generality. Wilson Dis. Op. at 1–2.
Respectfully, the panel’s framing of the right is squarely
within the approach taken by our Circuit, as Judge Jordan acknowl-
edges.
See
Jordan Dis. Op. at 1 (recognizing that “[t]here is admit-
tedly some support in our cases for the panel’s approach”). For
example, in
Doe v. Moore
,
But instead of accepting this broad framing of the supposed
rights at stake, this Court “endeavor[ed] to create a more careful
description of the asserted right in order to analyze its importance.”
Id.
A “careful description of the fundamental interest at issue here,”
we explained, “allows us to narrowly frame the specific facts before
us so that we do not stray into broader ‘constitutional vistas than
are called for by the facts of the case at hand.’”
Id.
at 1344 (quoting
Williams v. Att’y Gen. of Ala.,
Similarly, in
Morrissey v. United States
, 871 F.3d 1260 (11th
Cir. 2017), the plaintiff alleged that the IRS’s disallowance of a
claimed deduction for IVF-related costs infringed “his fundamental
*24
right to reproduce.”
Id.
at 1268. We recognized that the Supreme
Court had “referred to procreation as ‘fundamental to the very ex-
istence and survival of the [human] race’ and as a ‘basic civil right[]
of man.’”
Id.
(alterations in the original) (quoting
Skinner v. Okla-
homa
,
The approach taken by these cases explains our framing of
the alleged “right” at issue here.
[9]
And while it is true that a plurality
of the Supreme Court has recognized, at a high level of generality,
“the fundamental right of parents to make decisions concerning the
care, custody, and control of their children,”
Troxel v. Granville
, 530
U.S. 57, 66 (2000) (plurality opinion), there is no accompanying sug-
gestion from the Court that plaintiffs asserting a supposed right un-
der this umbrella are exempt from the “careful description” re-
quirement found elsewhere in the case law. To the contrary, as a
recent decision makes clear, the Court has continued to define
*25
alleged unenumerated rights narrowly so as to maintain fidelity to
the facts before it in each case.
See Muñoz
,
There is also the fact that most of the cases concerning pa-
rental rights “pertain to issues of education, religion, or custody.”
Eknes-Tucker II
,
Child labor laws were at issue in Prince v. Massachusetts , 321 U.S. 158 (1944). The petitioner, a Jehovah’s Witness, was the aunt *26 and custodian of a nine-year-old girl. Id. at 159, 161. After allowing the girl to assist with sidewalk preaching efforts, the petitioner was charged with furnishing the girl with magazines to sell and permit- ting her to work in violation of the law. Id. at 160, 162. Pointing to Meyer and Pierce , the Court said that it “is cardinal with us that the custody, care and nurture of the child reside first in the parents, whose primary function and freedom include preparation for obli- gations the state can neither supply nor hinder.” Id. at 166. At the same time, the Court recognized “that the state has a wide range of power for limiting parental freedom and authority in things af- fecting the child’s welfare” and that the “state’s authority over chil- dren’s activities is broader than over like actions of adults.” Id. at 167–68.
In
Wisconsin v. Yoder
,
The Supreme Court’s other parental-rights cases mostly in-
volve custody issues.
Stanley v. Illinois
,
In Santosky v. Kramer , 455 U.S. 745 (1982), the Supreme Court considered the constitutionality of New York’s statutory scheme governing the termination of parental rights in cases of per- manent neglect. Id. at 748–52. The Court held that the parents in that case were deprived of due process, as the statute at issue re- quired only a “fair preponderance of the evidence” to support a finding of permanent neglect. Id. at 747, 768. Along the way to that conclusion, the Court referenced the “fundamental liberty in- terest of natural parents in the care, custody, and management of their child.” Id. at 753.
And
Troxel
concerned the constitutionality of Washington’s
statute that afforded “[a]ny person” the ability to petition a court
for visitation rights.
We are not free to divorce the facts of these cases from the
rules they set forth.
See, e.g.
,
Edwards v. Prime, Inc.
,
Both Judge Jordan and Judge Rosenbaum rely most heavily
on another case,
Parham v. J. R.
,
In
Parham
, a group of minors brought a procedural-due-pro-
cess challenge to Georgia’s statutory scheme governing the admis-
sion of children to mental hospitals. 442 U.S. at 587–88. Im-
portantly, this scheme allowed parents to apply for their child’s
hospitalization.
Id.
at 590–91. Judges Jordan and Rosenbaum are
correct that the Court considered the interests of the parents in
reaching a conclusion as to the procedural protections owed to the
plaintiffs under the Due Process Clause.
Id.
at 601–04. Drawing
from its precedents, the Court said that a parent’s “high duty . . . to
recognize and prepare [their children] for additional obligations”
includes a duty to “recognize symptoms of illness and to seek and
follow medical advice.”
Id.
at 602 (second alteration in the original)
(quoting
Pierce
,
The Court ultimately concluded that “some kind of inquiry should be made by a ‘neutral factfinder’ to determine whether the statutory requirements for admission are satisfied,” but it rejected a “formalized, factfinding hearing” because that could lead to a “significant intrusion into the parent-child relationship.” Id. at 606, 610. “Pitting the parents and child as adversaries,” said the Court, “often will be at odds with the presumption that parents act in the best interests of their child.” Id. at 610.
In determining
Parham
’s relevance to this case, context is
again key.
See Nat’l Pork Producers
,
Importantly, the Supreme Court later rejected an attempt to
turn
Parham
into the decision some of the dissenters want it to be. In
Cruzan ex rel. Cruzan v. Director, Missouri, Department of Health
,
Attempts to distinguish away
Cruzan
come up empty. Judge
Rosenbaum reads
Parham
to recognize a fundamental right and
then says that
Cruzan
, with its different facts, did not limit that
right.
See
Rosenbaum Dis. Op. at 19–23. But
Cruzan
did not distin-
guish
Parham
on any of the grounds offered by Judge Rosenbaum.
Instead, the Court in
Cruzan
disagreed with the petitioner’s view of
“constitutional law,” as evidenced by the petitioner’s reading of
Parham
, which is like the reading offered by Judges Jordan and Ros-
enbaum.
See Cruzan
,
In short, while some of the dissenters chant Parham “like a mantra,” they “cannot give [ Parham ] substance that it lacks.” Sec. & Exch. Comm’n v. Jarkesy , 144 S. Ct. 2117, 2138 (2024). Parham does not lead to the conclusion that the Parent Plaintiffs have a constitutional right to override Alabama’s decision regarding the availability of the medications prohibited for use by minors under the Act.
Thus, though purporting to simply apply Supreme Court
precedent, both Judge Jordan and Judge Rosenbaum would have
us mark out new terrain.
[12]
While the Supreme Court’s substantive-
*34
due-process precedents do not rule out such a move, they do de-
mand a showing that a right is “deeply rooted in [our] history and
tradition” and “essential to our Nation’s ‘scheme of ordered lib-
erty.’”
Dobbs
,
The approach taken by the district court—and by extension
those defending its decision—does not pay “careful ‘respect [to] the
teachings of history.’”
Moore v. City of East Cleveland
,
Judges Jordan and Rosenbaum similarly fail to supply the
needed historical support. This holds true even if we assume that
they correctly framed the alleged right at stake. Finding the proper
level of specificity does not exempt one from “engag[ing] in a care-
ful analysis of the history of the right at issue.”
Dobbs
, 597 U.S. at
238. And neither Judge Jordan nor Judge Rosenbaum has demon-
strated that the ability to obtain medically-approved or non-exper-
imental treatment, despite state regulation to the contrary, is
*36
“deeply rooted in [our] history and tradition.”
Id.
at 237 (alteration
in the original) (quoting
Timbs
,
This lack of history should not be surprising given that
“States traditionally have had great latitude under their police pow-
ers to legislate as to the protection of the lives, limbs, health, com-
fort, and quiet of all persons.”
Medtronic, Inc. v. Lohr
,
Importantly, a state’s exercise of this authority is not contin-
gent on the approval of the expert class. The Constitution’s con-
tours are not shaped by expert opinion.
See Dobbs
,
Additionally, neither Judge Jordan nor Judge Rosenbaum
has assembled a historical record demonstrating that adults them-
selves possess the constitutional right to access the medications at
issue, or any specific medication, for that matter. And the weight
of the authority indicates that the opposite is true. Many of our
sister circuits “have rejected arguments that the Constitution pro-
vides an affirmative right of access to particular medical treatments
reasonably prohibited by the Government.”
Abigail All. for Better
Access to Developmental Drugs v. von Eschenbach
, 495 F.3d 695, 710
(D.C. Cir. 2007) (en banc);
see id.
at 710 n.18 (collecting cases);
Mitchell v. Clayton
,
For all these reasons, the panel was correct to conclude that the Parent Plaintiffs have failed to establish the existence of a fun- damental right. I write further, though, to highlight additional doubts that I have about the Parent Plaintiffs’ arguments.
First, even if the historical record lent credence to the idea
that there was a parental right to obtain medically approved or
non-experimental medications in the face of governmental prohi-
bition, I am skeptical that this right would be implicated here. “[I]n
areas where there is medical and scientific uncertainty,” state legis-
latures are afforded “wide discretion to pass legislation.”
Gonzales
v. Carhart
,
Below, the district court extended the Constitution’s protec- tions despite considerable uncertainty, based in part on its conclu- sion that Alabama failed to produce “evidence showing that transi- tioning medications jeopardize the health and safety of minors suf- fering from gender dysphoria.” Eknes-Tucker I , 603 F. Supp. 3d at 1145. But that statement is not quite right. [14] As I explain in my discussion of rational-basis review, Alabama did in fact produce ev- idence to that effect. [15] See infra at 43–47. And recent revelations only serve to confirm the impropriety of the district court’s inter- vention. I make note of them not because they change our review of the district court’s order, but because they highlight the issues *40 that often arise when courts extend the Constitution’s protections to areas subject to all sorts of uncertainty.
For example, when the district court entered the order un-
der review, it concluded that “no country or state in the world cat-
egorically bans the[] use” of puberty blockers and cross-sex hor-
mones “as Alabama has.”
Eknes-Tucker I
,
The district court also relied heavily on the Standards of
Care promulgated by WPATH,
Eknes-Tucker I
, F. Supp. 3d at 1138–
39, 1145, which one dissenter considers the “leading authority” in
*41
this area. Rosenbaum Dis. Op. at 29. But recent revelations indi-
cate that WPATH’s lodestar is ideology, not science. For example,
in one communication, a contributor to WPATH’s most recent
Standards of Care frankly stated, “[o]ur concerns, echoed by the
social justice lawyers we spoke with, is that evidence-based review
reveals little or no evidence and puts us in an untenable position in
terms of affecting policy or winning lawsuits.” This only reinforces
the district court’s improper reliance on the scientific claims of an
advocacy organization to craft constitutional law. Indeed, as oth-
ers have recognized, WPATH’s Standards of Care “reflect not con-
sensus, but merely one side in a sharply contested medical debate
over sex reassignment surgery.”
Gibson v. Collier
,
These revelations only further underscore the reality that a
judge is not fit, in a preliminary posture and on a limited record, to
remove matters like this one from an ongoing public debate. Even
assuming parents possessed a right to compel access to certain
*42
medical treatments for their children, this right certainly does not
include the ability to access substances that gravely threaten a
child’s development.
Cf. Prince
,
Some substantive-due-process cases may be hard. Jordan
Dis. Op. at 1. This one is not. Judge Jordan reminds us “that it is a
constitution we are expounding.” Jordan Dis. Op. at 2 (alteration
adopted) (quoting
Home Bldg. & Loan Ass’n v. Blaisdell
,
B. Equal Protection Judge Rosenbaum’s and Judge Wilson’s dissents also disa- gree with our equal-protection holding, arguing that the Act dis- criminates based on sex and transgender status. Rosenbaum Dis. Op. at 46–63; Wilson Dis. Op. at 3–5. But the Act applies equally to everyone regardless of their sex or transgender status. And transgender status is not a classification protected by the Equal Pro- tection Clause. These points are discussed in turn below.
1. The Act does not discriminate based on sex. Supposedly, the Act unconstitutionally discriminates based on sex because “but for the Minors’ birth-assigned sex,” they could access puberty blockers and cross-sex hormones. Rosenbaum Dis. Op. at 49. For example, Judge Rosenbaum notes that the Act pro- hibits a “birth-assigned boy” from “tak[ing] estrogen” for the pro- scribed purpose while a “birth-assigned girl” can take estrogen to cure “an estrogen deficiency.” Id. In other words, Judge Rosen- baum argues that the Equal Protection Clause requires Alabama to make cross-sex hormones and puberty blockers available for the *44 proscribed purpose so long as Alabama allows the use of puberty blockers and cross-sex hormones for other purposes.
Therein lies the problem with her reasoning: The Act dis- criminates based on purpose, not sex. The Act prohibits everyone under the age of nineteen—regardless of their sex—from using cross-sex hormones or puberty blockers “for the purpose of attempt- ing to alter the appearance of or affirm [their] perception of [their] gender or sex, if that appearance or perception is inconsistent with [their] sex.” Act § 3–4(a) (emphasis added); Ala. Code § 43-8-1(18). Likewise, the Act allows everyone under the age of nineteen—re- gardless of their sex—to use cross-sex hormones and puberty block- ers for other purposes, such as treating central precocious puberty. Act § 4(b)(2).
True, the Act uses sex-specific terminology.
See
Wilson Dis.
Op. at 4–5. The Act prohibits prescribing or administering “su-
praphysiologic doses of testosterone . . . to females” and prescrib-
ing or administering “supraphysiologic doses of estrogen to males.”
Act § 4(a)(2)–(3). But this sex-specific language actually preserves
evenhandedness. Because of biological realities, the cross-sex hor-
mone regimen that one undergoes is necessarily dependent on
one’s sex. Males cannot use testosterone for the prohibited pur-
pose, and females cannot use estrogen for the prohibited purpose.
To the extent that the Act includes provisions that reference only
one sex,
see id.
, it simply reflects these realities to equally proscribe
cross-sex hormones for both males and females. If the Act re-
stricted only the use of testosterone—but not estrogen—for the
*45
proscribed purpose, it would discriminate against females. And if
the Act restricted only the use of estrogen—but not testosterone—
for the proscribed purpose, it would discriminate against males. In
other words, the Act uses sex-specific language because it regulates
sex-specific medications. And, as noted in our panel opinion, “[t]he
regulation of a medical procedure that only one sex can undergo
does not trigger heightened constitutional scrutiny unless the reg-
ulation is a ‘mere pretex[t] designed to effect an invidious discrim-
ination against members of one sex or the other.’”
Eknes-Tucker II
,
Judge Rosenbaum and Judge Wilson both invoke
Bostock v.
Clayton County
,
Bostock
relied heavily on the unique text of Title VII—
particularly, the words “because of,” “otherwise . . . discriminate
*46
against,” and “individual.”
Eknes-Tucker II
,
Next, two dissents cite
Glenn v. Brumby
,
Judge Rosenbaum responds that it is a form of stereotyping
to prohibit minors from taking transitioning medications.
See
Ros-
enbaum Dis. Op. at 52–53. But there is a difference between pro-
hibiting biological men from wearing dresses,
see Brumby
, 663 F.3d
at 1314, 1318–19, and prohibiting minor boys from taking estrogen
“for the purpose of attempting to alter the appearance of or affirm
the minor’s perception of his . . . gender or sex, if that appearance
or perception is inconsistent with [his] sex,” Act § 4(a). The former
restriction is a stereotype about how men should dress, the latter
restriction is based on physical differences between males and fe-
males. And, as the Supreme Court has recognized, “[p]hysical dif-
ferences between men and women . . . are enduring.”
United States
v. Virginia
,
Overall, the Act applies equally to minor males and minor
females. Both sexes
can
use puberty blockers and cross-sex hor-
mones to treat a medical disorder, Act § 4(b)(2), but neither sex
may use puberty blockers and cross-sex hormones “for the purpose
of attempting to alter the appearance of or affirm [their] perception
of [their] gender or sex, if that appearance or perception is incon-
sistent with [their] sex.”
Id.
§ 4(a). Thus, our panel correctly held
that the Act is subject to rational-basis scrutiny, not intermediate
scrutiny.
Eknes-Tucker II
,
2. The text of the Act is neutral as to transgender status, and
transgender status is not a quasi-suspect classification.
Judge Rosenbaum also claims that the Act triggers interme-
diate scrutiny because transgender status is a quasi-suspect classifi-
cation. Rosenbaum Dis. Op. at 58–63. But as our panel opinion
explained, even if transgender status is a quasi-suspect classifica-
tion, the Act would not trigger heightened scrutiny because it dis-
criminates solely based on “purpose.” Act § 4(a);
Eknes-Tucker II
,
More generally, transgender status is not a quasi-suspect
classification in the first place. While sitting en banc, we already
declined to recognize transgender status as a quasi-suspect classifi-
cation.
See Adams ex rel. Kasper v. Sch. Bd. of St. Johns Cnty.
, 57 F.4th
791, 803 n.5 (11th Cir. 2022) (en banc) (expressing “grave ‘doubt’
that transgender persons constitute a quasi-suspect class”). Fur-
ther, the Supreme Court “has not recognized any new constitu-
tionally protected classes in over [five] decades, and instead has re-
peatedly declined to do so.”
Ondo v. City of Cleveland
,
v. Castillo
,
Judge Rosenbaum would chart new territory by treating
transgender status as a quasi-suspect classification. The district
court never held that,
see Eknes-Tucker I
,
Furthermore, transgender persons are not a “discrete
group” that exhibits “obvious” or “distinguishing” characteristics.
Lyng
,
Finally, transgender people are not “politically powerless.”
Lyng
,
Because the Act does not discriminate based on a suspect or
a quasi-suspect classification, the Act is subject to rational-basis re-
view.
Id.
at 440, 446. To satisfy rational-basis review, Alabama
needs only one “conceivable basis” to proscribe cross-sex hor-
mones and puberty blockers for minors.
See Jones v. Governor of Flor-
ida
,
C. Rational-Basis Review Under rational-basis review, the question “is simply whether the challenged legislation is rationally related to a legitimate state *53 interest.” Lofton v. Sec’y of Dep’t of Child. & Fam. Servs. , 358 F.3d 804, 818 (11th Cir. 2004). Alabama satisfied this remarkably lenient standard for at least five reasons.
First
, Alabama provided significant evidence that the medi-
cations covered by the Act are dangerous and ineffective. Alt-
hough the district court disagreed with that evidence, it acknowl-
edged that Alabama “offer[ed] some evidence that transitioning
medications pose certain risks.”
Eknes-Tucker I
, 603 F. Supp. 3d at
1145. That is sufficient to satisfy the rational-basis test. The Ala-
bama legislature is entitled to look at the competing evidence and
draw its own conclusions.
Heller
,
Alabama provided declarations from six medical experts— three endocrinologists (including two pediatric endocrinologists), a clinical psychologist, a psychotherapist, and a pediatrician—who testified to the acute dangers posed to children by these medica- tions. Alabama also submitted six journal articles and public-health reports that documented concerning data and evidence about the proscribed treatments. And Alabama provided written testimony from detransitioners, including Sydney Wright (discussed above), *54 KathyGrace Duncan (Appendix A), Carol Frietas (Appendix B), and Corinna Cohn (Appendix C). Although the district court’s order discussed the testimony of Dr. James Cantor and Sydney Wright, the district court never mentioned any of the other evidence de- scribed in this paragraph. See Eknes-Tucker I , 603 F. Supp. 3d at 1142–43, 1145–46.
Alabama also presented evidence that healthcare authorities and medical organizations in several countries—including Eng- land, Finland, and Sweden—urge (and, in some cases, mandate) that doctors rarely prescribe puberty blockers and cross-sex hor- mones. In Sweden, for example, doctors can provide minors with puberty blockers and cross-sex hormones in “exceptional cases” only. Sweden’s National Board of Health and Welfare determined that “the risks of puberty suppressing treatment with GnRH-ana- logues and gender-affirming hormonal treatment currently out- weigh the possible benefits.”
The information that has emerged since the panel’s opinion only confirms what the panel already concluded: Alabama has a rational basis for the Act. As discussed earlier, in March 2024, for example, England’s NHS announced “that there is not enough ev- idence to support the safety or clinical effectiveness of [puberty suppressing hormones] to make the treatment routinely available” in England. NHS Clinical Policy, supra n.3, at 3. And, in April 2024, Dr. Hillary Cass published the results of a four-year review of pu- berty blockers and cross-sex hormones in minors. See The Cass Re- view, supra n.2. While formulating her report, Cass chaired a *55 policy working group that the NHS commissioned in January 2020. Id. at 75. The policy working group systematically examined “the published evidence on the use of puberty blockers and [cross-sex] hormones in children and young people” with the goal of “in- form[ing] [NHS’s] policy position on their future use.” Id. Cass found “no evidence that puberty blockers improve body image or dysphoria, and very limited evidence for positive mental health outcomes.” Id. at 179. Cass also concluded that puberty blockers may negatively impact “neurocognitive development” and will likely compromise a patient’s “bone density.” Id. at 178. Regarding cross-sex hormones, Cass’s “systematic review” found inadequate evidence supporting the “widespread” view—expressed in Judge Rosenbaum’s dissent—that cross-sex hormones “reduce[] suicide risk” for children suffering from gender dysphoria. Id. at 186, 195. Cass also provided multiple reasons to question the reliability of WPATH and concluded that the most recent iteration of the Stand- ards of Care “overstates the strength of the evidence” supporting its recommendations. Id. at 132; see also id. at 129–30 (concluding that WPATH’s Standards suffer from a low “[r]igour of develop- ment” and the lack of “[e]ditorial independence,” among other things).
Second , Alabama had a rational basis to prohibit cross-sex hormones and the other proscribed medications for minors be- cause minors cannot appreciate the life-altering nature of the med- ical treatments. The law frequently limits the ability of minors to consent to certain activities. And evidence in the record suggests that minors are incapable of knowingly consenting to the use of the *56 proscribed medications. Alabama presented evidence from many detransitioners who uniformly testified that they were not aware of the long-term impacts of the treatments they underwent. Next, Alabama provided declarations from several parents who testified to the negative effects of cross-sex hormones and puberty blockers on their children, even if their children suffered from gender dys- phoria and desired medical transition. Furthermore, Alabama pre- sented written testimony from nine parents who said that doctors, therapists, and other practitioners pressured them to start their children on cross-sex hormones and puberty blockers or otherwise circumvented their wishes. For example, when one mother’s twelve-year-old daughter said that she was a boy, the mother asked her daughter’s gender clinic for a counseling referral before hor- mone therapy. But an endocrinologist rebuffed the mother’s re- quest, stating in front of the twelve-year-old daughter that the mother needed “to get on board” with providing puberty blockers and hormones if she did not “want [her] daughter to commit sui- cide.”
This record evidence is consistent with information that has come to light after the district court issued its order. As Dr. Cass found in her April 2024 study, we know very little about the long- term risks of these medications, which makes the idea of “informed consent” nearly impossible for anyone, but especially for children and adolescents. See The Cass Review, supra n.2, at 193–97.
Third , as discussed above, studies show that most children with gender dysphoria grow out of it. As one of Alabama’s experts *57 testified, “every study without exception has come to the identical conclusion: Among prepubescent children who feel gender dys- phoric, the majority cease to want to be the other gender over the course of puberty—ranging from 61–88% desistance across the large, prospective studies.” Alabama also presented evidence that children are starting to identify as transgender because of social contagion, not gender dysphoria. Teenage girls, in particular, are starting to suddenly identify as transgender even if they have no history of gender dysphoria as children. And, according to one of Alabama’s experts, “[t]he majority of cases appear to occur within clusters of peers and in association with increased social media use and especially among people with autism or other neurodevelop- mental or mental health issues.” Even the Plaintiffs’ expert, Dr. Linda Hawkins, testified that gender clinics are “seeing an increase in youth . . . who are exploring gender . . . . [T]hat is something that is gaining popularity right now.” Alabama has a legitimate in- terest in preventing harm to children who often do not suffer from gender dysphoria, and even if they do, likely will grow out of it. It is thus rational to require children to wait to undergo this type of medical treatment until they are adults.
Fourth
, notwithstanding assurances from organizations like
WPATH, there are significant unknowns about these treatments,
which recent developments only serve to highlight. The district
court’s order relied on WPATH’s Standards of Care,
Eknes-Tucker
I
,
For instance, in a leaked recording of a WPATH Panel, Dr. Daniel Metzger—an endocrinologist—frankly discussed the diffi- culties of helping children and adolescents understand the effects of cross-sex hormones and puberty blockers. Id. at 184–85. He acknowledged, “the thing you have to remember about kids is that we’re often explaining these sorts of things to people who haven’t even had biology in high school yet.” Id. at 184. Later at the same panel, he said, “it’s always a good theory that you talk about fertil- ity preservation with a 14 year old, but I know I’m talking to a blank wall.” Id. at 192. Another provider at the same panel discussed the difficulty in helping nine-, ten-, and eleven-year-olds understand the long-term effects of puberty blockers on their fertility. Id. at 193. “I’m definitely a little stumped,” she admitted. Id.
In one of the leaked documents, Dr. Marci Bowers—a gyne- cological surgeon and WPATH’s President—states: “[A]cknowl- edgement that de-transition exists to even a minor extent is consid- ered off limits for many in our community.” Id. at 111. Bowers agreed with this practice, continuing, “I do see talk of the [detran- sition] phenomenon as distracting from the many challenges we face.” Id. These recent revelations only further confirm the *59 unsettled nature of this field, the risks involved for Alabama’s youth, and the need for judicial caution.
Finally , it is rational for Alabama to conclude that there are alternatives to childhood use of cross-sex hormones and puberty blockers. Although the suicide rate is high in the transgender com- munity, Dr. Cass’s April 2024 study concluded that “there is no ev- idence that gender-affirmative treatments reduce [suicidality.]” See The Cass Review, supra n.2, at 195. The report continued that the available evidence “suggests that these deaths are related to a range of other complex psychosocial factors and to mental illness.” Id. Alabama could rationally conclude that suicidality—which is a mental-health problem—should be treated with counseling, medi- cation, and other forms of psychotherapy.
Comparatively, none of the studies that Judge Rosenbaum’s dissent relies on provide a solid basis for her claim that “studies have repeatedly shown that gender-affirming hormone therapy markedly decreases suicidality and depression among transgender minors who want such care.” Rosenbaum Dis. Op. at 41 n.22. Start with the Tordoff study. Judge Rosenbaum claims that puberty blockers and “gender-affirming” hormones led to a “60% decrease in depression” and a “73% decrease in suicidality.” Id; see Diana M. Tordoff, et al., Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care , 5 J. Am. Med. Ass’n Network Open 1, (2022). But this is misleading, as almost all the participants who did not take puberty blockers or cross-sex hormones dropped out of the study before its conclusion, weakening any potential *60 conclusions. Tordoff, et al., Mental Health Outcomes , 5 J. Am. Med. Ass’n Network Open at at 1; Tordoff, et al. , Mental Health Outcomes , Supplemental Online Content, eTable 2, eTable 3.
Next is the Green study. Judge Rosenbaum claims that this study demonstrates a “40% decrease in depression and suicidality.” Rosenbaum Dis. Op. at 41 n.22. It is true that the study represented that receipt of hormone therapy was associated with lowered odds of recent depression and the serious consideration of suicide in the past year. Amy E. Green et al., Association of Gender-Affirming Hor- mone Therapy With Depression, Thoughts of Suicide, and Attempted Su- icide Among Transgender and Nonbinary Youth , 70 J. of Adolescent Health 643, 647 (2022). But significantly, the authors also noted that, because of the study’s cross-sectional design, “causation [could not] be inferred.” Id. at 648.
Judge Rosenbaum next relies on the Turban study, which she claims demonstrates a “statistically significant decrease in sui- cidal ideation.” Rosenbaum Dis. Op. at 41 n.22; see Jack L. Turban et al., Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation , 145 Pediatrics 1, 5–6 (2020). This study pulled data from the 2015 US Transgender Survey, but out of the 3,494 participants in the study, only 89 reported that they received puberty blockers. Id. at 3–4. The authors reported that “[t]reatment with pubertal suppression among those who wanted it was associated with lower odds of lifetime suicidal ideation when compared with those who wanted pubertal suppression but did not receive it.” Id. at 5. But near the end of their paper, the authors admit that the design of *61 their study “does not allow for determination of causation.” Id. at 7. Further, as detailed in a review of the study, there are good rea- sons to question the data set used by the authors, for it “included older respondents who, in fact, had no opportunity to obtain these drugs and so cannot be used for comparison.” Michael Biggs, Pu- berty Blockers and Suicidality in Adolescents Suffering from Gender Dys- phoria , 49 Archives of Sexual Behav. 2227, 2228 (2020). The Turban study also fails to control for preexisting psychological problems. In order to provide true insight, the study would need to measure “the respondent’s psychological problems before [the puberty blockers were] prescribed or withheld.” Id. (emphasis omitted). Without this information, “a negative association found many years after treatment is compatible with three scenarios: puberty blockers reduced suicidal ideation; puberty blockers had no effect on suicidal ideation; [or] puberty blockers increased suicidal idea- tion, albeit not enough to counteract the initial negative effect of psychological problems on eligibility.” Id. And finally, England’s National Institute for Health and Care Excellence excluded the Turban study from its evidence report because the data for puberty blockers was “not reported separately from other interventions.” Therefore, the Turban study, as with the others already discussed, provides no probative causal connection between suicidality and the use of puberty blockers.
Finally, Judge Rosenbaum turns to the Allen study, which she claims documents a “75% decrease in suicidality.” Rosenbaum Dissenting Op at 41 n.22; see Luke Allen et al., Well-being and Sui- cidality Among Transgender Youth after Gender-affirming Hormones , 7 *62 Clinical Practice in Pediatric Psychology 302, 306 (2019). But like the other studies, the Allen study’s authors could not conclude that the hormone treatments were “causally responsible for the benefi- cial outcomes observed,” because, in this case, the study lacked a control group. Id. at 309. The authors also did not screen for whether the patient was actively receiving psychotherapy, which further weakens any inference of causation. See id. at 308.
In all, none of these studies provides real support for Judge Rosenbaum’s discussion of the supposed benefits of cross-sex hor- mones and puberty blockers. Nor do they undermine Cass’s four- year independent review of the available evidence, which con- cluded that “there is no evidence that gender-affirmative treatments reduce [suicidality.]” See The Cass Review, supra n.2, at 195 (em- phasis added). All of this underscores that this is an issue for the political branches, not the judicial branch.
Ultimately, the Alabama legislature is entitled to review all
the available evidence and decide whether to circumscribe cross-
sex hormone and puberty blocking medications for the purposes
set forth in the Act. On rational-basis review, our role is not “to
judge the wisdom, fairness, or logic of [that] legislative choice[].”
Beach Commc’ns
,
III. CONCLUSION
Alabama enacted an entirely rational law. The Fourteenth
Amendment, as informed by text, history, tradition, and our prec-
edents, does not prevent Alabama from doing so. Instead of acting
as a “super-legislature,”
Day-Brite Lighting Inc. v. Missouri
, 342 U.S.
421, 423 (1952), our Court has correctly allowed Alabama to “safe-
guard[] the physical and psychological well-being” of its minors,
Globe Newspaper Co.
,
Appendix A: KathyGrace Duncan [20] 1. I am over the age of 18 years and am not a party to this ac- tion. I have actual knowledge of the following facts and if called upon to testify to them could and would do so competently. I am submitting this Declaration in support of Defendants’ opposition to Plaintiffs’ Motion for a Temporary Restraining Order and Pre- liminary Injunction.
2. Alabama’s Vulnerable Child Compassion and Protection Act (“VCCAP”) is a necessary, potentially life-saving law that will protect vulnerable children and their parents from the heartbreak- ing regret, irreversible physical changes, sexual dysfunction and emotional pain that I have experienced after undertaking medical and surgical interventions aimed at “transitioning” me from a fe- male to a “male.”
3. From a very young age, I was what is called today “gender non-conforming.” I preferred male clothing, I thought I was a “boy” and I wanted to live as one.
4. I grew up in a dysfunctional family in which my mother was often the victim of my father’s emotional and verbal abuse. As a result I internalized the message that “my dad would love me if I were a boy.”
*65 5. Sexual abuse by a family member between the ages of 10 and 12 further convinced me that being a girl meant being unsafe and unlovable.
6. In sixth grade, I learned about female to male transsexuals. I believed that my distress was caused by not having the “right” body and the only way to live a normal life was to medically tran- sition and become a heterosexual male.
7. At age 19, I began living as a man named Keith and went to a therapist who formally diagnosed me with gender dysphoria. I began testosterone and a year later had a mastectomy. At the time, I believed it was necessary so that what I saw in the mirror matched what I felt on the inside.
8. I never viewed my condition as touching on mental health issues, and neither did the therapist who diagnosed me. The ques- tion of whether my self-perception and desire to transition was re- lated to [my] mental health issues was never explored.
9. After 11 years passing as a man and living what I thought was a relatively “happy” and stable life (which included having a number of girlfriends), I realized that I was living a lie built upon years of repressed pain and abuse. Hormones and surgery had not helped me resolve underlying issues of rejection, abuse, and sexual assault. I came to understand that my desire to live as a man was a symptom of deeper unmet needs.
10. With the help of life coaches and a supportive community, I returned to my female identity and began addressing the underly- ing issues that had been hidden in my attempt to live as a man. I *66 experienced depression that I had repressed for years and grieved over the irreversible changes to my body.
11. If someone had walked with me through my feelings in- stead of affirming my desire to transition, then I would have been able to address my issues more effectively and not spend so many years making and recovering from a grave mistake.
12. Alabama’s VCCAP Act is necessary and essential because it will give children and adolescents a chance to walk through their feelings and address their underlying issues effectively without be- ing pulled onto the affirmation conveyor belt. Hormones and sur- gery are irreversible decisions that children and adolescents are in- capable of making.
Appendix B: Carol Frietas 1. I am over the age of 18 years and am not a party to this ac- tion. I have actual knowledge of the following facts and if called upon to testify to them could and would do so competently. I am submitting this Declaration in support of Defendants’ opposition to Plaintiffs’ Motion for a Temporary Restraining Order and Pre- liminary Injunction.
2. Alabama’s Vulnerable Child Compassion and Protection Act (“VCCAP”) is a necessary, potentially life-saving law that will protect vulnerable children and their parents from the heartbreak- ing regret, irreversible physical changes, and emotional pain that I have experienced after undertaking medical and surgical interven- tions aimed at “transitioning” me from a female to a “male.” 3. As a youth, I was what today is called “gender non-conform- ing,” but I lived in a household where gender expression was strictly aligned with cultural stereotypes. I was not allowed to wear boys’ clothes or play boys’ sports.
4. At puberty I realized I was same-sex attracted with crushes on girls. I became depressed and anxiety-ridden as I feared what “being gay” might mean to how I lived my life and my family rela- tionships. I dropped out of school.
5. At age 20, I began to meet other LGBT youth and my life stabilized. However, I also learned that many masculine females, like me, felt that they were “born in the wrong body” and were transitioning, so I adopted that persona.
6. I went to a gender therapist who diagnosed me with gender dysphoria and told me that transition was the only treatment that would alleviate my discomfort and anxiety.
7. However, at that time there were gatekeeping standards for gender transition, which required that I first live as man for six months, including using a male name, showing a male appearance, and using male spaces. I had very large breasts and could not pass for a male in male spaces, so I did not pursue testosterone at that time. I viewed myself as a male trapped in the “wrong body,” but my mental health otherwise was stable.
8. In 2014, I revisited the idea of transitioning, believing it would make me feel better because I was undergoing trauma in various forms. My grandmother who had practically raised me died. I had suffered severe abuse and neglect in childhood, and in retrospect believe I was experiencing symptoms of PTSD from that. I had just become a new mother a couple of months before my brother-in-law committed suicide.
9. I spiraled downward and wanted out. I couldn’t commit su- icide because I was a mother, so I returned to the idea of transition, believing it would help me feel better. By that time the require- ments for testosterone had lessened. I went to Planned Parenthood for testosterone and was given it right away, with no information. I was not given any information on uterine atrophy, vaginal atrophy, or other effects of testosterone and the staff did not talk about any of my emotional or mental health issues. *69 10. Four months after starting testosterone, I went to a plastic surgeon for a mastectomy. I needed a letter from a therapist and received one from the therapist who had affirmed me and origi- nally recommended transition. As was true with testosterone, I was not given any information about the procedure. Instead I had a consultation with the surgeon, who said “this is what we are go- ing to do,” drew on my chest, took pictures and asked me what I wanted out of the surgery. He said “we’ll create a masculine look- ing chest, you’ll look great.”
11. During the first four months on testosterone menstruation stopped, my sex drive went way up, my voice deepened, and facial and body hair came in. As I continued on testosterone, my person- ality changed drastically and my verbal abilities declined. Testos- terone lowered and muted my emotions and empathy, but also gave me a lot of energy and a sense of a high. My depression and anxiety worsened to the point that I was having such severe panic attacks that I could not leave home. I told my doctors that I thought the testosterone was making the anxiety worse, but they said no.
12. I went to a psychiatrist . . . specifically to deal with the de- pression and I was provided with an anti-depressant that really worked. I felt mentally stable and able to address the trauma that led me to transition.
13. Within a month of starting the anti-depressant, I realized that I had not needed to transition. It was the biggest mistake I had ever made. I did not detransition for a year because I couldn’t *70 believe that it was so easy, i.e. , that anti-depressants alleviated my depression and enabled me to think clearly and reason better. This allowed me [to] address my internalized homophobia and child- hood abuse through therapeutic means.
14. Meanwhile, my health began going downhill. Before going on testosterone, I had no health problems. After being on it for four years, I was pre-diabetic, had high cholesterol, and had a high red blood cell count to the point that doctors were recommending that I donate blood to reduce the volume.
15. I stopped taking testosterone and four months later my blood work was back down to normal. I thought to myself “How do they [doctors] not know about this?” Going off testosterone al- lowed me to finally sleep. I felt like I never slept all the time that I was taking testosterone. Going off testosterone also helped with empathy and other emotions. My personal relationships, including my relationship with my wife, were better.
16. I believe that healthcare providers did not ask me about mental health issues because they believed that those issues were caused by gender dysphoria and that transitioning would fix the problem. In fact, the opposite was true.
17. I would have been spared physical, psychological, and emo- tional losses if I had received a proper diagnosis and treatment for PTSD and depression before undergoing years of medical and sur- gical interventions. Alabama’s VCCAP Act is necessary and essen- tial because it will give children and adolescents the chance to work through and address their underlying issues such as depression or *71 PTSD effectively without being pulled onto the affirmation con- veyor belt. Hormones and surgery are irreversible decisions that children and adolescents are incapable of making.
Appendix C: Corinna Cohn My name is Corinna Cohn. I am over the age of 19, I am qualified to give this declaration, and I have personal knowledge of the matters set forth herein.
In or about 2 nd grade, I saw a psychologist for problems re- lated to being bullied and emotional regulation. After less than a year, my parents chose to discontinue therapy. I continued to be bullied and had problems forming friendships. Other boys ex- cluded me from social activities. Later in elementary school I be- gan to pray to be made into a girl, which I thought would allow me to fit in better. This became a fixation for me.
In high school, I confessed to my parents that I wanted to become a woman. They brought me to see the same psychologist I’d had as a child, and she diagnosed me with having gender iden- tity disorder. Upon receiving my diagnosis, my parents again chose to discontinue my therapy. I continued to have problems socializ- ing at school and experienced depression and anxiety on a daily ba- sis.
At the age of 17, I gained access to the Internet. This was prior to the popularization of the World Wide Web, but I was able to use message boards . . . in order to find other members of what today would be called the “trans community.” Adult transgender women befriended me, supplied me with validation and support, and provided information on how I could transition to become a transgender woman.
At the age of 18, I resumed my sessions with my psycholo- gist with the goal of receiving a prescription for cross-sex hormones and eventual sex reassignment surgery. Due to my prior relation- ship with my psychologist, I was able to gain a letter of recommen- dation to an endocrinologist and was prescribed estrogen. The en- docrinologist was referred to me by transgender friends on the In- ternet. I began living as a woman and had my legal identification updated to reflect my chosen name.
I had sex reassignment surgery in Neenah, Wisconsin in 1994. I was only 19 years old. Securing the appointment required letters from two therapists along with a letter from my endocrinol- ogist. My surgeon told me I was the second-youngest patient he had operated on. The surgery involved the removal of my testicles, penectomy, and vaginoplasty. It was successful and without com- plication.
After healing from my sex change surgery I thought that my transition journey was over. I discontinued therapy, and I began focusing on my career. I found it was easier to socialize and make new friends with my new confidence and feelings of being my au- thentic self. As I reached my late twenties, my friends began pair- ing off and starting families. I discovered that it was very difficult to find a partner who wanted to do the same with me.
Although I was in denial for several years, I eventually real- ized that my depression and anxiety related to my gender identity had not resolved. It was not unusual for me to spend entire week- ends in my room crying and entertaining thoughts of suicide.
In my mid-thirties I became interested in radical feminism. I am not a feminist, nor have I ever been, but I wanted to reconcile how feminist concepts applied to people like myself: males who try to turn ourselves into women. One of the concepts I found pivotal was the feminist criticism of biological essentialism, which chal- lenges the idea that men and women are destined to fulfill rigid sex roles. Once I understood this criticism I realized that my more ste- reotypically feminine attitudes and behaviors did not therefore make me a woman, but rather a feminine man. In retrospect, my self-perception of being a woman also required that I overlook or discount traits that are more stereotypically masculine. Although it took time for this realization to fully sink in, a side effect was that I stopped having bouts of depression and anxiety related to my gen- der identity. I have not had any depressive episodes related to gen- der identity in ten years. As a teenager I was unprepared to under- stand the consequences of my decision to medicalize my transition despite the rigorous controls that were in place to ensure that pa- tients would not be harmed from gender affirming care.
. . .
I wish I could persuade other boys who wish to become women that the changes they seek are only superficial. Hormones and surgery are unable to reveal an authentic self, and anyone who promises otherwise is, in my opinion, deliberately misleading young people to follow a one-way track to a lifetime of medicaliza- tion. Although some people may choose to transition, and may even enjoy a higher quality of life, there is no reason why this *75 irreversible decision needs to be made in adolescence. Adults who advocate for adolescent transition do so without understanding what tradeoffs early transition entails, which includes the loss of fertility, the likelihood of sexual dysfunction, and the likelihood of surgical complication inflicted at an early age from elective proce- dures. Unfortunately, I do understand some of these tradeoffs *76 W ILSON , Circuit Judge, dissenting from the denial of rehearing en banc, joined by J ORDAN , Circuit Judge:
This case presents numerous questions “of exceptional im- portance” worthy of en banc review. Fed. R. App. P. 35(a)(2). See- ing that this case implicates the contours of substantive due pro- cess, fundamental rights, and equal protection, it is difficult to en- vision issues of greater importance.
I. Substantive Due Process The divergent descriptions of the fundamental right at issue and disagreement over whether substantive due process protects that right demonstrate a need for rehearing en banc.
The district court relied on the Supreme Court’s decision in
Troxel v. Granville
, among others, which recognized the fundamen-
tal right of parents to “make decisions concerning the care, cus-
tody, and control of their children.”
II. Equal Protection Like Judge Rosenbaum, I am also concerned with the panel’s equal protection analysis—particularly its quick and improper dis- missal of Bostock and Brumby . The panel concludes that because Bostock and Brumby involved gender stereotyping in the context of employment discrimination, their holdings are irrelevant here. I am not so sure.
In
Brumby
, we explained that “[a] person is defined as
transgender precisely because of the perception that his or her be-
havior transgresses gender stereotypes,” and accordingly held that
“discrimination against a transgender individual because of her
gender-noncomformity is sex discrimination.”
Glenn v. Brumby
, 663
F.3d 1312, 1316–17 (11th Cir. 2011). Our analysis drew from “foun-
dational cases” in which the Supreme Court “concluded that dis-
criminatory state action could not stand on the basis of gender ste-
reotypes.”
Id.
at 1319. But these cases were not limited to the em-
ployment context and included examples of gender stereotyping in
the provision of social security benefits, military benefits, educa-
tion, and child support payments.
Id.
at 1319–20. The same is true
of
Bostock
, which held that “discrimination based on . . .
transgender status necessarily entails discrimination based on sex.”
Bostock v. Clayton Cnty.
,
panel looks only to
Bostock
and
Brumby
’s employment outcome, ra-
ther than drawing from the underlying reasoning in each case to
determine when gender and sex stereotyping rises to the level of a
constitutional violation.
[2]
See Fowler v. Stitt
,
Judge Brasher’s concurrence, in which he states that the Act
does not contain a sex classification, is also indicative of the need
for en banc review.
Eknes-Tucker
,
The Act as it stands now shapes the way parents of
transgender children may care for their children, while parents of
cisgender children remain unaffected. Should a parent of a child be
prevented from seeking medical care
because of
the sex of their
child?
See Stanton
,
* * * For these reasons, it is difficult to envision issues of greater importance than those presented here. We should have reheard this case en banc. Accordingly, I respectfully dissent from our re- fusal to do so.
*81 J ORDAN , Circuit Judge, joined by R OSENBAUM and J ILL P RYOR , Cir- cuit Judges, dissenting from the denial of rehearing en banc.
Substantive due process is hard. Acknowledging the com- plexity of the doctrine, I write to discuss what I perceive to be some analytical flaws in the panel’s opinion.
I
In this case, the panel characterized the liberty interest in
part by asking whether there is a history of recorded uses of tran-
sitioning medications for transgender individuals (e.g., puberty
blockers and cross-sex hormone treatments) as of 1868, when the
Fourteenth Amendment was ratified. Finding no such history, the
panel concluded that there is no fundamental right for parents to
treat their children with such medications.
See Eknes-Tucker v. Gov-
ernor of Alabama
,
The panel’s decision necessarily means that the fundamental
right of parents to obtain medical treatment for their children ex-
tends only to procedures and medications that existed in 1868, and
not to modern advances like the polio vaccine (developed in the
1950s), cardiac surgery (first performed in 1893), organ transplants
(first successfully completed in 1954), and treatments for cancer
like radiation (first used in 1899) and chemotherapy (which started
in the 1940s).
See
Judge Rosenbaum Dissent at Part II.A.2. There
is admittedly some support in our cases for the panel’s approach,
see Morrissey v. United States
,
Some have said that in constitutional law the “[l]evel of gen-
erality is everything[.]”
L.W. v. Skrmetti
,
II
When it comes to challenges to legislation, the substantive
component of the Due Process Clause “protects those fundamen-
tal rights and liberties which are, objectively, deeply rooted in this
Nation’s history and tradition, . . . and implicit in the concept of
ordered liberty, such that neither liberty nor justice would exist if
they were sacrificed[.]”
Washington v. Glucksberg
,
The panel here in part relied on the substantive due process
aspect of our decision in
Bendiburg v. Dempsey
, 909 F.2d 463, 468
(11th Cir. 1990), calling it the “most relevant” Eleventh Circuit
precedent dealing with “parents’ liberty interest to control the up-
bringing of their children.”
Eknes-Tucker
,
In
Bendiburg
, a father asserted a substantive due process
claim based on the involuntary insertion of a certain catheter on
*84
his son by private parties allegedly acting in concert with state offi-
cials. The district court in
Bendiburg
characterized the substantive
due process claim as one alleging abusive
executive
action, and re-
jected it: “The most widely accepted view is that substantive due
process is violated by government conduct that ‘shocks the con-
science’ or when the government engages in action ‘which offends
those canons of decency and fairness which express the notions of
justice of English speaking peoples.’ The question before the court
is thus whether the evidence of record suggests state conduct that
was so shocking or egregious as to give rise to a claim for damages
under the concept of substantive due process. The court finds that
it does not.”
Bendiburg v. Dempsey
,
On appeal, the
Bendiburg
panel affirmed the district court’s
decision and rejected the father’s substantive due process claim.
But it too viewed the claim as based on allegedly abusive executive
action, and not as a challenge to enacted legislation. So it too ap-
plied the “shocks the conscience” standard in rejecting the father’s
claim, agreeing with the district court that the “circumvention of
parental authority for a five day period [to install the catheter] did
not rise to a level sufficiently egregious or shocking to sustain a
substantive due process claim with respect to severance of the par-
ent-child relationship.”
The panel here should not have viewed
Bendiburg
as the
“most relevant” of our cases. First, the “shocks the conscience”
standard governs substantive due process claims based on abusive
executive action, and not challenges to legislation like we have in
this case. Second, we have explained that the “shocks the con-
science” standard can apply even when there is no fundamental
right at stake: “Where a fundamental liberty interest does not exist,
substantive due process nonetheless protects against the arbitrary
and oppressive exercise of government power. Executive action is
arbitrary in a constitutional sense when it ‘shocks the conscience.’”
Waldman v. Conway
, 871 F.3d 1283, 1292 (11th Cir. 2017) (citing
Lewis
,
III
In cases involving substantive due process challenges to leg-
islation, the Supreme Court has required a “careful description of
the asserted fundamental liberty interest.”
Glucksberg
, 521 U.S. at
721 (citation and internal quotation marks omitted). But “[t]his
does not mean that [courts] must define the asserted right at the
most specific level, thereby sapping it of a universal valence and
moral force it might otherwise have. It means, simply, that we must
executive) conduct the relevant inquiry is whether the conduct “shocked the
conscience.”
See Gilmere v. City of Atlanta
,
pay close attention to the precise liberty interest the litigants have
asked us to vindicate.”
McDonald v. City of Chicago
,
In
Michael H. v. Gerald D.
,
The Supreme Court has described the rights of parents vis-
à-vis their children generally. It has, for example, referred to those
rights as “the fundamental right of parents to make decisions con-
cerning the care, custody, and control of their children.”
Troxel v.
Granville
,
Accordingly, I cite with confidence to the dissent of Justice
Stevens in
McDonald
,
A
Let’s now review some of the relevant substantive due pro-
cess cases, starting with
Meyer v. Nebraska
,
The Supreme Court held that the law—which the Nebraska Supreme Court had interpreted to apply only to so-called modern languages such as Spanish, French, German, and Italian—violated a fundamental liberty interest protected by the Due Process Clause of the Fourteenth Amendment. The Court concluded that the teacher’s “right . . . to teach [German] and the right of parents to en- gage him so to instruct their children . . . are within the liberty of the [Fourteenth] [A]mendment.” Id. at 400 (emphasis added). It came to this conclusion without examining the historical record to see if *89 there was an enshrined practice and tradition in the United States in 1868 of teaching German to elementary school students. Having identified a fundamental right, the Court in Meyer then turned to Nebraska’s justification for the law. The Court thought it insufficient that “the purpose of the legislation was to promote civic development by inhibiting training and education of the immature in foreign tongues and ideals before they could learn English and acquire American ideals.” Id. at 401. Though “the state may do much, go very far, indeed, in order to improve the quality of its citizens, physically, mentally and morally, . . . the indi- vidual has certain fundamental rights which must be respected. The protection of the Constitution extends to all, to those who speak other languages as well as to those born with English on the tongue. Perhaps it would be highly advantageous if all had ready understanding of our ordinary speech, but this cannot be coerced by methods which conflict with the Constitution—a desirable end cannot be promoted by prohibited means.” Id. The law was invalid because there was not a sufficient justification for its restrictions: “No emergency has arisen which renders knowledge by a child of some language other than English so clearly harmful as to justify its inhibition with the consequent infringement of rights long freely enjoyed. We are constrained to conclude that the statute as applied is arbitrary and without reasonable relation to any end within the competency of the state.” Id. at 403.
Next is
Pierce v. Society of Sisters
,
Applying Meyer , the Court held that the act violated a fun- damental liberty interest of the Society of Sisters, of the Hill Mili- tary Academy, and of parents:
Appellees are engaged in a kind of undertaking not inherently harmful, but long regarded as useful and meritorious. Certainly there is nothing in the present records to indicate that they have failed to discharge their obligations to patrons, students, or the state. And there are no peculiar circumstances or present emergencies which demand extraordinary measures relative to primary education. . . . [W]e think it en- tirely plain that the Act of 1922 unreasonably inter- feres with the liberty of parents and guardians to direct the upbringing and education of children under their con- trol . As often heretofore pointed out, rights guaran- teed by the Constitution may not be abridged by leg- islation which has no reasonable relation to some pur- pose within the competency of the state. The funda- mental theory of liberty upon which all governments in this Union repose excludes any general power of the state to standardize its children by forcing them to accept instruction from public teachers only.
*91 Id. at 534–35 (emphasis added). As in Meyer , the Court in Pierce did not perform a laser-fo- cused historical analysis to see if Catholic or private military schools were ingrained in the fabric of the Republic as of 1868. In- deed, had the Court engaged in such an analysis, it would have dis- covered that there was no accepted or ingrained practice of Cath- olic schools at the time the Fourteenth Amendment was ratified. To the contrary, although American Catholics in the 19th Century had “long maintained their own schools,” they had to contend with anti-Catholic sentiment and discrimination and had to fight to pro- tect their ability to maintain independent and sectarian religious schools. See Matthew Steilen, Parental Rights and the State Regulation of Religious Schools , 2009 B.Y.U. Educ. & L.J. 269, 318–30 (2009); Brandi Richardson, Eradicating Blaine’s Legacy of Hate: Removing the Barrier to State Funding of Religious Education , 52 Cath. U. L. Rev. 1041, 1050–54 (2003); Joseph P. Viteritti, Blaine’s Wake: School Choice, the First Amendment, and State Constitutional Law , 21 Harv. J.L. & Pub. Pol’y 657, 669 (1998). The Blaine Amendments to the United States Constitution (which failed) and to many state constitutions (which generally passed) both before and after the ratification of the Fourteenth Amendment were generally meant to prevent gov- ernment financial aid to Catholic schools. See Toby Heytens, School Choice and State Constitutions , 86 Va. L. Rev. 117, 137–38 (2000) (“The Blaine Amendments arose out of this historical context, and the conclusion that they were driven by the Protestant/Catholic divide is unmistakable, despite the fact that none of the amend- ments refer specifically to Roman Catholics or Catholic schools. *92 This appears to be the scholarly consensus.”). Had the Court in Pierce defined the right as that of a Catholic organization to run its own religious schools in place of otherwise compulsory public ed- ucation, or to the right of parents to send their children to a Cath- olic school, it would not and could not have found a fundamental liberty interest, much less a substantive due process violation. B
Lest anyone think that
Meyer
and
Price
—and their non-spe-
cific characterizations of the liberty interests at issue—are relics of
a bygone era, there are modern substantive due process cases
which engage in the same type of analysis and describe the right at
issue in more general terms. I discuss four such cases as examples.
In
Loving v. Virginia
,
Id.
at 12 (citations omitted). Needless to say,
Loving
would have
been decided differently if the right at issue had been framed spe-
cifically as of 1868, for “interracial marriage was illegal in most
[s]tates in the 19th century[.]”
Planned Parenthood of S.E. Pa. v. Casey
,
Another relevant case is
Lawrence v. Texas
, 539 U.S. 558
(2003), in which the Supreme Court set aside, on substantive due
process grounds, the Texas criminal convictions of two adult gay
men who had engaged in consensual sodomy in the privacy of the
home. In so doing the Court overruled
Bowers v. Hardwick
, 478 U.S.
186 (1986), and said that
Bowers
had “misapprehended” the perti-
nent liberty interest as the “‘fundamental right [of ] homosexuals
to engage in sodomy.’”
Lawrence
,
*95 The case . . . involve[s] two adults who, with full and mutual consent from each other, engaged in sexual practices common to a homosexual lifestyle. The pe- titioners are entitled to respect for their private lives. The State cannot demean their existence or control their destiny by making their private sexual conduct a crime. Their right to liberty under the Due Process Clause gives them the full right to engage in their con- duct without intervention of the government.
Id.
at 578. Had the pertinent liberty interest in
Lawrence
been de-
fined at a “very specific level” (as in
Bowers
), there is no way the case
would have been decided the way it was.
See
William J. Rich, Mod-
ern Constitutional Law: Liberty and Equality § 11.7 (3d ed. 2011)
(“In the sexual orientation context . . . a majority of the Justices
resolved the doctrinal tension by defining the liberty interest in
broad terms that included a right to private choices about sexual
intimacy regardless of sexual orientation.”).
[3]
Then there is
Obergefell
, where the Supreme Court held that
same-sex couples have a fundamental right, protected by substan-
tive due process, to marry. The Court recognized that “[h]istory
and tradition guide and discipline [the fundamental rights] in-
quiry,” but cautioned that they “do not set its outer boundaries.
*96
That method respects our history and learns from it without allow-
ing the past alone to rule the present.”
Obergefell
,
Objecting that this does not reflect an appropriate framing of the issue, the respondents refer to . . . Glucksberg , 521 U.S. [at] 721, . . . which called for a “‘careful description’” of fundamental rights. They assert the petitioners do not seek to exercise the right to marry but rather a new and nonexistent “right to same-sex marriage.” Glucksberg did insist that lib- erty under the Due Process Clause must be defined in a most circumscribed manner, with central reference to specific historical practices. Yet while that approach may have been appropriate for the asserted right there involved (physician-assisted suicide), it is incon- sistent with the approach this Court has used in dis- cussing other fundamental rights, including marriage and intimacy. Loving did not ask about a “right to in- terracial marriage”; Turner did not ask about a “right of inmates to marry”; and Zablocki did not ask about a “right of fathers with unpaid child support duties to marry.” Rather, each case inquired about the right to marry in its comprehensive sense, asking if there was a sufficient justification for excluding the relevant class from the right. That principle applies here. If *97 rights were defined by who exercised them in the past, then received practices could serve as their own continued justification and new groups could not in- voke rights once denied. This Court has rejected that approach, both with respect to the right to marry and the rights of gays and lesbians.
Id. at 671 (citations omitted and paragraph structure altered). Thus, the Court in Obergefell “focused on the individual right to marry” and not on the right of gay persons to marry. See Stone, et al., Constitutional Law, at 917.
C
In each of the cases discussed above, the Supreme Court did in fact find that there was a fundamental right. So, for the sake of completeness, I’ll discuss two Supreme Court decisions in which the Court did not find a fundamental right and yet still defined the rights at issue generally rather than granularly, as done by the panel here.
I’ll start with
Glucksberg
. In
Glucksberg
, the Supreme Court
was called upon to determine whether a state may constitutionally
ban and criminalize physician-assisted suicide.
See Glucksberg
, 521
U.S. at 707–08. Five physicians, three terminally ill patients, and a
nonprofit organization sued the state of Washington, seeking a
declaration that a state statute criminalizing the promotion of sui-
cide—where a defendant “knowingly causes or aids another person
to attempt suicide”—was facially unconstitutional.
See id.
at 707
(citing Wash. Rev. Code § 9A.36.060(1) (1994)). Before the Supreme
Court, the physicians and the Ninth Circuit propounded various
*98
definitions of the liberty interest at stake, including a “liberty to
choose how to die,” “a right to die,” and a “right to choose a hu-
mane, dignified death.”
Id.
at 722 (internal quotations omitted).
The Court in
Glucksberg
rejected those purported definitions as
overly broad and instead held that the question was “whether the
‘liberty’ specially protected by the Due Process Clause includes a
right to commit suicide which itself includes a right to assistance in
doing so.”
Id.
at 723. It did not, however, define the right as “a right
to commit suicide with another’s assistance” via a legal dosage of
morphine or other opioids, barbiturates, or benzodiazepines, (such
as pentobarbital or secobarbital), or other cardiotoxic agents.
Thus, even the more precise formulation in
Glucksberg
of the right
at issue—a formulation later Supreme Court cases deemed “cir-
cumscribed,”
see Obergefell
,
The Court in
Glucksberg
then went on to address whether the
right to suicide and its inherent right to assistance in doing so was
deeply rooted in this nation’s history, and held that it was not.
See
Let me next turn to
Dobbs
, the Supreme Court’s most recent
substantive due process decision. In
Dobbs
, the Court revisited the
*99
abortion question once more. In overruling two of its decisions—
Roe v. Wade
,
D
I have selectively chosen the cases summarized above, but have done so for a reason—to make the point that the Supreme Court’s substantive due process cases are not always reconcilable and that trying to make sense of them requires consideration of the jurisprudence as a whole. The lower federal courts generally do not have the luxury of picking and choosing their preferred Su- preme Court decisions. Our job, difficult as it may sometimes be, is to try to make sense of a jurisprudential landscape which often is neither linear nor consistent. And to do that, we must consider all of the relevant Supreme Court precedent in a given area of law, not just those cases that support a given proposition. Sometimes that may require choosing one set of Supreme Court decisions over another. But if that is the case, we have a dual obligation—an ob- ligation to admit that we are indeed choosing, and an obligation to explain why we have exercised that choice in a certain way. Consti- tutional adjudication is necessarily an exercise in judgment. Cf. *101 Erwin Chemerinsky, Foreword—The Vanishing Constitution , 103 Harv. L. Rev. 43, 99 (1989) (“The Court must explain why the value choice made by the constitutional claimant is unworthy of judicial protection and why the particular decision is better left to the elected branches of government.”).
If the panel here was going to demand that the right at issue be defined at a “very specific level” to include the use of specific transitioning medications for transgender individuals—medica- tions which did not exist in 1868—it had to account for how the fundamental right was framed generally in Meyer and Pierce . And it had to explain why it chose not to follow cases like Loving , O’Con- nor , Lawrence , and Obergefell , and their more general approach to defining liberty interests protected by substantive due process. [4] IV
As I see this case, the ultimate resolution of the plaintiffs’ substantive due process claims depends on two questions. The first is whether parents have a fundamental right, protected by substan- tive due process, to obtain medically-approved treatment for their children. If the answer to that question is yes, the second inquiry is whether Alabama has shown that its laws are narrowly tailored *102 to serve a compelling interest. See Glucksberg , 521 U.S. at 721 (“[T]he Fourteenth Amendment ‘forbids the government to in- fringe . . . “fundamental” liberty interests at all, no matter what process is provided, unless the infringement is narrowly tailored to serve a compelling state interest.’”).
But we are reviewing only the grant of a preliminary injunc-
tion, and not a permanent injunction issued after a full trial on the
merits. In this procedural posture we do “not concern [ourselves]
with the merits of the controversy. . . . No attention is paid to the
merits of the controversy beyond that necessary to determine the
presence or absence of an abuse of discretion.”
Di Giorgio v. Causey
,
488 F.2d 527, 528–29 (5th Cir. 1973). Our task is to determine
whether the district court abused its discretion in, for example, con-
cluding that the plaintiffs demonstrated a substantial likelihood of
success on the merits.
See, e.g.
,
Ashcroft v. Am. Civ. Liberties Union
,
542 U.S. 656, 666, 669 (2004) (concluding that the district court’s
determination as to likelihood of success was not an abuse of dis-
cretion);
LSSI Data Corp. v. Comcast Phone, LLC
,
Some courts have incorrectly framed the right as the right
of parents to seek medical treatments that the state has banned.
See
L.W.
,
One cannot describe the fundamental right at stake (the first
step in the substantive due process analysis) by attaching to it the
challenged restriction which, at the end of the day, might (or might
not) be narrowly tailored to serve a compelling state interest (the
second step in the substantive due process analysis). The asserted
risks or detriments associated with the right in this context of
transgender treatments “[are] properly considered only after the
right is deemed fundamental.”
Id.
at 716 (Rogers, J., dissenting).
If the right could be defined as including the legal prohibi-
tion being challenged under substantive due process,
Meyer
would
have characterized the liberty interest as the right to teach a school
subject in German when the state had deemed such teaching inap-
propriate and harmful to the social fabric. But that is not how
Meyer
was decided. The Supreme Court framed the liberty interest
more generally as the right to teach a subject in German, and only
*105
after identifying that right as fundamental did it consider whether
Nebraska had sufficiently justified its prohibition.
See Meyer
, 262
U.S. at 400–01, 403. The same goes for
Pierce
,
Loving
,
O’Connor
,
Lawrence
, and
Obergefell
.
See generally Griswold
,
Again, I see no abuse of discretion by the district court.
“[P]arents have, in the first instance, a fundamental right to decide
whether their children should (or should not) undergo a given
treatment otherwise available to adults, and the government can
take the decisionmaking reins from parents only if it comes for-
ward with sufficiently convincing reasons to withstand judicial
scrutiny.”
L.W.
,
*106
I do not doubt the general authority of the government to
take legislative action with respect to the medical care of children.
See Otto v. City of Boca Raton
,
To repeat, we are here on appeal of a preliminary injunction. As explained by Judge Rosenbaum in her dissent, the district court made extensive factual findings. See Eknes-Tucker v. Marshall , 603 F. Supp. 3d 1131, 1141–43 (M.D. Ala. 2022); Judge Rosenbaum Dissent at Part I & II.B.2. The panel in this case should have applied clear error review to the district court’s factual findings and, once the factual landscape was settled, should have then considered whether the district court abused its discretion in preliminarily concluding that Alabama had not shown that its laws were narrowly tailored to serve a compelling state interest. See Lebron v. Secretary , 710 F.3d 1202, 1218–19 (11th Cir. 2013) ( Jordan, J., concurring) (citing Su- preme Court and Eleventh Circuit cases for the proposition that generally an appellate court does not decide the merits of a case when reviewing a preliminary injunction). The panel, however, did neither.
By framing the right in a too-specific way, the panel was able to default to the rational basis test, which in turn allowed it to ig- nore the district court’s factual findings and not demand any real *107 justification from Alabama for its laws. And, to compound this er- ror, Judge Lagoa’s statement regarding the denial of rehearing en banc now engages in its own evaluation of non-record evidence, provides its own characterization of the facts, and conducts its own weighing of the evidence. That, in my view, is upside-down appel- late review.
V
In
Adams v. School Board of St. Johns County
,
R OSENBAUM , Circuit Judge, joined by J ILL P RYOR , Circuit Judge, and joined as to Sections I and II by J ORDAN , Circuit Judge, dis- senting from the denial of rehearing en banc:
If ever a case warranted en banc review, this is it. The panel opinion’s reasoning strips every parent in this Circuit of their fun- damental right to direct that their children receive any medical treatment (no matter how well-established and medically en- dorsed)—except for those medical treatments in existence as of 1868. Yes, 1868—before modern medicine. So in the states of Ala- bama, Florida, and Georgia, blistering, blood-letting, and leeches are in, but antibiotics, antivirals, and organ transplants are out.
Yet nothing in the law handcuffs us to nineteenth-century medicine. To the contrary, Supreme Court precedent recognizes parents’ fundamental right to direct that their child receive well- established, evidence-based, non-experimental medical treatment, subject to medically accepted standards and a physician’s independ- ent examination and medical judgment. See Parham v. J.R. , 442 U.S. 584, 602 (1979). Treatments that do not meet these demanding cri- teria fall outside the Parham right. But for treatments that do, the State cannot interfere with parents’ fundamental right to access those treatments for their children without meeting a demanding constitutional burden.
The district court’s factual findings—that the treatment at issue here is well-established, evidence based, medically, endorsed, and non-experimental—place that treatment squarely within Par- ham ’s fundamental right. See Eknes-Tucker v. Marshall , 603 F. Supp. *109 3d 1131, 1144–46 (M.D. Ala. 2022) (“ Eknes-Tucker I ”). And the panel opinion didn’t find any of the district court’s factual findings to be clearly erroneous. So the panel opinion should have—but did not—apply strict scrutiny in conducting its due-process review. Had the panel opinion done so, it would have had to conclude that it is substantially likely that Alabama’s law does not pass muster under the Due Process Clause. Yet the panel opinion neither ap- plies strict scrutiny nor reaches the answer that strict scrutiny de- mands.
The panel opinion is not just bad for Plaintiffs here. It is dis-
astrous for
all
parents in the Eleventh Circuit. That’s so because,
in reaching its result, the panel opinion applies an unprecedented
methodology that requires us to consider how the particular treat-
ment at issue “inform[ed] the meaning of the Fourteenth Amend-
ment at the time it was ratified—July 9, 1868.”
Eknes-Tucker v. Gov-
ernor of Alabama
,
But of course, no treatment that didn’t exist or wasn’t dis- covered by 1868 could hope to “inform[] the meaning of the Four- teenth Amendment at the time it was ratified.” Id. So the 1868 Methodology imposes a standard that no modern medical treat- ment can satisfy. And despite its claim to history and tradition, the 1868 Methodology breaks from precedent and the reality of scien- tific development. It is unsupportable. But because we did not re- hear this case en banc, the 1868 Methodology is the law of this Cir- cuit.
The panel opinion does not stop there. Compounding its
legal errors, the panel opinion then turns a blind eye to the Ala-
bama law’s sex-based classifications, just because they arise in the
context of medical treatment. But precedent contains no such ex-
ception. To the contrary, it subjects sex-based classifications to
heightened constitutional scrutiny.
See, e.g.
,
Miss. Univ. for Women v.
Hogan
,
It’s substantially likely that the Fourteenth Amendment tol- erates neither the due-process nor equal-protection threats that Al- abama’s law poses and that the panel opinion permits. But the panel opinion distorts the due-process and equal-protection anal- yses, stacking the deck in the Alabama law’s favor. And once the panel opinion concludes (wrongly) that parents have no fundamen- tal right at stake (because transitioning medications weren’t around in 1868) and that the Alabama law doesn’t discriminate on the basis of sex or transgender status, it deals the rational-basis review card rather than subjecting the Act to strict or intermediate scrutiny, re- spectively. Then, the game is in the bag for Alabama because the Alabama law—like most legislation—satisfies rational-basis review.
What’s more, the Lagoa Statement now tries to engage in a do-over—in some places retreating from and in other places com- pounding the panel opinion’s legal errors. And it relies heavily on materials that were before neither the district court nor the panel. Not only that, but the Lagoa Statement substitutes its own factual findings based on these extraneous and untested outside sources for the district court’s factual findings, which the panel opinion did not find to be clearly erroneous. The proper mechanism for a do- over is the en banc process—not using a statement respecting the denial of rehearing to paper over the panel opinion’s flawed reason- ing, reinvent the factual record, and disclaim the panel opinion’s repercussions.
In short, the panel opinion is wrong and dangerous. Make no mistake: while the panel opinion continues in force, no modern medical treatment is safe from a state’s misguided decision to out- law it, almost regardless of the state’s reason. Worse still, if a state bans a post-1868 treatment, no parent has legal recourse to provide their child with that necessary, life-saving medical care in this Cir- cuit. And if an individual can’t access a medical treatment because of their sex or transgender status, they are similarly without legal recourse.
Because of the life-altering and unconstitutional conse- quences the panel opinion inflicts on the parents and children of this Circuit, I respectfully dissent from denial of rehearing en banc.
I. BACKGROUND Alabama’s Vulnerable Child Compassion and Protection Act (“Act”) criminalizes the administration of puberty blockers and hormone therapy to minors—but only if that treatment is “per- formed for the purpose of attempting to alter the appearance of or affirm the minor’s perception of his or her gender or sex” and even in that case, only “if that appearance or perception is inconsistent with the minor’s sex ” at birth. S.B. 184, Ala. 2022 Reg. Sess. § 4(a) (Ala. 2022) (emphasis added) . Otherwise, administration of puberty blockers and hormone therapy to minors is legal. I refer at times in this dissent to these drugs as “transitioning medications” because that is what the district court called them. See Eknes-Tucker I , 603 F. Supp. 3d 1131 at 1139.
Plaintiffs, a group of transgender [1] minors and their parents as well as medical providers and a reverend whose congregation includes transgender minors and their families (“Parents” and *113 “Minors” [2] ), sued to challenge the Act. Id. at 1141. The United States intervened on behalf of the Parents and Minors. Also in sup- port of the Parents and Minors, twenty-two healthcare organiza- tions filed an amicus brief. [3] Id. As for Alabama, [4] fifteen states filed an amicus brief in support of its position and the Act. Id.
The Parents and Minors sought a preliminary injunction to halt the Act’s operation while the suit was pending. Id. Following an evidentiary hearing where the district court received and re- viewed reams of medical evidence and heard from several wit- nesses, the district court concluded that the Parents and Minors *114 were “substantially likely to succeed on their Substantive Due Pro- cess claim” and “on their Equal Protection claim.” Id. at 1146, 1148. Based on these conclusions and the determination that the Parents and Minors had shown each of the other preliminary-injunction factors (they would suffer irreparable harm without an injunction, and the balance of harms and public interests favored the Parents and Minors), the district court preliminarily enjoined the Act. Id. at 1151.
In reaching this decision, the district court made several fac- tual findings based on the evidence it saw and heard. I summarize those findings below.
The World Professional Association for Transgender Health (“WPATH”) considers “transitioning medications as established medical treatments and publishes a set of guidelines for treating gender dysphoria in minors with these medications.” Id. at 1139. [5] *115 And as the district court found, at least 22 major medical organiza- tions—the American Medical Association, the American Academy of Pediatrics, the American Pediatric Society, the Association of American Medical Colleges, and the Association of Medical School Pediatric Department Chairs, to name just a few [6] —in the United States “endorse [the WPATH] guidelines as evidence-based meth- ods for treating gender dysphoria in minors.” Id. Indeed, the dis- trict court noted, Dr. Armand H. Antommaria, an expert in bioeth- ics and treatment protocols for adolescents suffering from gender dysphoria, emphasized that “transitioning medications are well-es- tablished, evidence-based methods for treating gender dysphoria in minors.” Id. at 1142. Not only that, but at the time of the hearing, “according to [Alabama’s] own expert, no country or state in the world categorically ban[ned] their use as Alabama ha[d].” [7] Id. at 1145.
WPATH’s work believe it has done just that, and they endorse and rely on the WPATH Standards of Care. The Lagoa Statement’s wholesale dismissal of WPATH’s work fails to reckon with the professional medical community’s embrace of WPATH as an evidence-based expert in the area of transgender medicine.
[6] These organizations are listed in footnote 3 of this dissent.
[7] The Lagoa Statement now tries to refute this finding by pointing to guidance from England’s National Health Service (“NHS”). Lagoa St. at 4–5, 30–31, 44– 45. Three responses. First, fact-finding in a statement respecting the denial of rehearing en banc is improper, and that is especially the case when the panel opinion did not find even one of the district court’s factual findings to be clearly erroneous. Second, the UK’s actions do not undermine the district court’s findings, in any case. The district court’s point was that no other coun- tries have “categorically ban[ned]” the use of transitioning drugs. That is still
Besides considering the medical community’s views, the dis- trict court also recounted that Parent Plaintiff Megan Poe the case. The Lagoa Statement points to only the United Kingdom’s revised guidelines to argue otherwise. But even in the UK, “gender affirming hor- mones” “are available as a routine commissioning treatment option for young people with continuing gender incongruence/gender dysphoria from around their 16th birthday.” Clinical Commissioning Policy: Prescribing of Gender Affirm- ing Hormones (masculinising or feminising hormones) as part of the Children and Young People’s Gender Service , Nat’l Health Serv. Eng. (Mar. 21, 2024), https://www.england.nhs.uk/wp-content/uploads/2024/03/clinical-com- missioning-policy-prescribing-of-gender-affirming-hormones.pdf [https://perma.cc/TB32-VHCV]. Plus, the UK’s temporary ban on puberty blockers that will dissolve in September permits current patients to continue their preexisting course of treatment and allows doctors to conduct clinical trials, TransActual CIC v. Sec’y of State for Health and Social Care [2024] EWHC 1936 (Admin), ¶ 148—but Alabama’s law has no exceptions. Third, it’s not clear that the “Cass Review” that the UK relies on would satisfy our courts’ evidence-reliability standards. See F ED . R. E VID . 702, 803(8)(B). “Most of the Review’s known contributors have neither research nor clinical experience in transgender healthcare.” Meredithe McNamara et al., An Evidence-Based Cri- tique of “The Cass Review” on Gender-affirming Care for Adolescent Gender Dysphoria 3 (July 1, 2024), https://law.yale.edu/sites/default/files/docu- ments/integrity-project_cass-response.pdf [https://perma.cc/N9Q7-AHKS]. Also, at least one commentator has noted that the Review’s conclusions are “deeply at odds with the [its] own findings . . . . Far from evaluating the evi- dence in a neutral and scientifically valid manner, the Review obscures key findings, misrepresents its own data, and is rife with misapplications of the scientific method.” Id. at 36; see also Chris Noone et al., Critically Appraising the Cass Report: Methodological Flaws and Unsupported Claims , OSFP RE P RINTS (June 9, 2024), https://osf.io/preprints/osf/uhndk [https://perma.cc/H9N9- N2XK]; D.M. Grijseels, Biological and Psychosocial Evidence in the Cass Review: A Critical Commentary , I NT . J. T RANSGENDER H EALTH , June 8, 2024, at 1. But then again, the point isn’t that the Lagoa Statement relies on inaccurate infor- mation—it’s that it’s not our role to fact-find in the first place. *117 “specifically described the positive effects transitioning treatments have had on her fifteen-year-old transgender daughter, Minor Plain- tiff Allison Poe.” Id. at 1142. As the court explained, “[d]uring her early adolescent years, Allis[]on suffered from severe depression and suicidality due to gender dysphoria.” Id. But after she started taking transitioning medications at the end of sixth grade, “her health significantly improved as a result.” Id. Indeed, Megan said her daughter was now “happy and ‘thriving.’” Id. But Megan “feared her daughter would commit suicide” if she were no longer able to take the medications. Id.
For its part, Alabama presented an expert psychologist wit- ness, but after reviewing his testimony, the district court was not impressed. See id . at 1142–43 . Rather, the district court gave “very little weight” to his testimony, noting that he practiced in Canada (not the United States); that his patients were, on average, thirty years old, and he had never treated minors with gender dysphoria; that he had no personal experience monitoring patients receiving transitioning medications; and that he lacked personal knowledge of the assessments or treatment methodologies any Alabama gen- der clinic employed. Id.
As for Alabama’s other live witness,
[8]
Sydney Wright—the
woman whose malpractice story the Lagoa Statement tells,
see
*118
Lagoa St. at 1–2—the district court found she took transitioning
medications for about a year, beginning when she was nineteen
years old.
See Eknes-Tucker I
,
Turning to Alabama’s “proffered purposes” for the Act, the district court found them to be “speculative, future concerns about the health and safety of unidentified children.” Eknes-Tucker I , 603 F. Supp. 3d at 1146. For starters, the district court noted that Ala- bama justified the Act by describing transitioning medications as “experimental.” Id. at 1140. But the district court found that, in fact, Alabama “produce[d] no credible evidence to show that tran- sitioning medications are ‘experimental.’” Id. at 1145; see also id. (“[Alabama] fail[s] to show that transitioning medications are ex- perimental.”). And more broadly, the district court found that Ala- bama’s stated purposes for the Act were “not genuinely compelling justifications based on the record evidence.” Id. at 1146.
To the contrary, based on all the evidence, the district court determined that the use of transitioning medications adhered to “medically accepted standards.” Id. Though the district court rec- ognized that “transitioning medications carry risks,” the court reit- erated the Supreme Court’s determination that “the fact that *120 pediatric medication ‘involves risks does not automatically transfer the power’ to choose that medication ‘from the parents to some agency or officer of the state.’” Id. (quoting Parham , 442 U.S. at 603). Rather, in the district court’s view, “[p]arents, pediatricians, and psychologists—not the State or this Court—are best qualified to determine whether transitioning medications are in a child’s best interest on a case-by-case basis.” Id.
We must accept the district court’s factual findings—all of
them—as true unless they are clearly erroneous.
See, e.g.
,
Hargray
v. City of Hallandale
,
The Lagoa Statement doubles down on this error. Of course, a statement respecting the denial of rehearing cannot find a district court’s factual findings to be clearly erroneous, especially when the panel opinion did not. But that doesn’t stop the Lagoa Statement from relying on unvetted sources from outside the rec- ord to argue, contrary to the district court’s factual findings, that transitioning medications are not well-established, evidence-based, or non-experimental treatment. This attempted do-over is just as wrong as the panel opinion, as I detail below.
II. The panel opinion wrongly concludes that the Parents are not substantially likely to succeed on the merits of their due-process claim.
The Fourteenth Amendment’s Due Process Clause prohibits any state from “depriv[ing] any person of life, liberty, or property, without due process of law.” U.S. Const. amend. XIV, § 1. It guar- antees both procedural and substantive rights. Washington v. Glucks- berg , 521 U.S. 702, 719–20 (1997). Among those guaranteed sub- stantive rights are “fundamental rights and liberties which are, ob- jectively, deeply rooted in this Nation’s history and tradition, and implicit in the concept of ordered liberty, such that neither liberty nor justice would exist if they were sacrificed.” Id. at 721 (cleaned up).
A law that burdens a fundamental right must survive strict
scrutiny, or it is unconstitutional.
See
,
e.g.
,
Lofton v. Sec’y of Dep’t of
Child. & Fam. Servs.
,
In contrast, we apply rational-basis review to evaluate the
constitutionality of a law that interferes with a right that is not fun-
damental. Rational-basis review is a sieve. It asks only whether
“there is any reasonably conceivable state of facts that could pro-
vide a rational basis” for the burden.
FCC v. Beach Commcn’s, Inc.
,
With this framework in mind, Section A shows that parents’ liberty interest in directing that their child receive well-established, evidence-based, non-experimental medical treatment, subject to medically accepted standards and a physician’s independent exam- ination and medical judgment, is a fundamental right, “deeply rooted in this Nation’s history and tradition, and implicit in the con- cept of ordered liberty, such that neither liberty nor justice would exist if they were sacrificed,” Glucksberg , 521 U.S. at 721 (cleaned up). Section B explains why the treatment the Parents seek here falls within that right’s scope. And because the Parents’ right is a fundamental one, Section C applies strict scrutiny and shows why it is substantially likely that the Act violates substantive due process. A. Parents’ liberty interest in directing that their children receive well-
established, evidence-based, non-experimental medical treatment, subject to medically accepted standards and a physician’s inde- pendent examination and medical judgment is a fundamental right.
1. The panel opinion erroneously dismisses Supreme Court precedent recognizing the fundamental right that the Parents assert.
*123
Due-process jurisprudence requires “a ‘careful description’
of the asserted fundamental liberty interest.”
Glucksberg
, 521 U.S.
at 721 (quoting
Reno v. Flores
, 507 U.S. 292, 302 (1993)). The Su-
preme Court has long recognized that “[i]t is cardinal . . . that the
custody, care and nurture of the child reside first in the parents,
whose primary function and freedom include preparation for obli-
gations the state can neither supply nor hinder.”
Prince v. Massachu-
setts
,
As a result, the Due Process Clause provides parents with
“the fundamental right . . . to make decisions concerning the care,
custody, and control of their children,” which is “perhaps the oldest
of the fundamental liberty interests recognized by th[e] Court.”
Troxel v. Granville
,
The Supreme Court has recognized that the umbrella of this
fundamental right shelters other, more specific rights. This is
where the “careful description” of the right comes in. For instance,
*124
the Court has held that a parent’s narrower, more carefully de-
scribed fundamental right to direct the education of his child falls
within the fundamental right “of the individual to . . . bring up chil-
dren.”
Meyer
,
Another carefully described fundamental right that the Su-
preme Court has recognized is parents’ fundamental right to direct
that their child receive well-established, evidence-based, non-exper-
imental medical treatment, subject to medically accepted standards
and a physician’s independent examination and medical judgment.
See Parham
,
In Parham , minors sought a declaratory judgment that Geor- gia’s voluntary-commitment procedures for children under the age of 18 violated due process, and the minors requested an injunction against the future enforcement of these procedures. Id. at 587–88. Under the procedures, a parent could apply for her child’s admis- sion for hospitalization. Id. at 591. The Parham minors challenged these procedures as a violation of their own procedural-due-pro- cess rights. See id. at 588.
In determining whether the procedures satisfied procedural
due process, the Supreme Court first identified the nature of the
*125
interests at stake.
See id.
at 599–606. After all, the process due de-
pends largely on the nature of the interest affected.
See Mathews v.
Eldridge
,
Among other parties’ interests to factor into the process-due calculation, the Supreme Court identified “the interests of the par- ents who have decided, on the basis of their observations and inde- pendent professional recommendations, that their child needs in- stitutional care.” Parham , 442 U.S. at 601–02. To evaluate the weight of that interest—and thus the process due—the Court dis- cussed the interest in more detail.
The Court first observed that “our constitutional system long ago . . . asserted that parents generally have the right, coupled with the high duty, to recognize and prepare their children for ad- ditional obligations.” Id. at 602 (cleaned up). In other words, the Court invoked the umbrella fundamental right of parents to direct the care, custody, and control of their children.
The Court continued, “Surely, this includes a ‘high duty’ to recognize symptoms of illness and to seek and follow medical ad- vice.” Id. Indeed, the Court explained, the law “historically . . . has recognized that natural bonds of affection lead parents to act in the best interests of their children.” Id. Thus, “[s]imply because the decision of a parent . . . involves risks does not automatically trans- fer the power to make that decision from the parents to . . . the state.” Id. at 603.
To illustrate this principle, the Court pointed to parents’ right to have “tonsillectom[ies], appendectom[ies], or other *126 medical procedure[s]” performed on their children. Id. These ex- amples show that the Court understood a parent’s fundamental right to direct the medical care of her child to refer to the category of well-established, evidence-based, non-experimental medical treatments. They also show that, with respect to this category of medical treatments, the Court recognized that a state’s invocation of risks, standing alone, does not justify a state’s decision to outlaw the treatment.
Ultimately, the Court concluded that parents “retain plenary authority to seek such care for their children, subject to a physi- cian’s independent examination and medical judgment.” Id. at 604. Thus, the Court recognized parents’ fundamental right to direct that their child receive well-established, evidence-based, non-exper- imental medical treatment, subject to medically accepted standards and a physician’s independent examination and medical judgment.
And the right that Parham recognized is the very fundamen- tal right that the Parents here invoke.
That the Supreme Court recognized such a fundamental right makes perfect sense when we consider the principles animat- ing substantive due process. Substantive due process protects only those rights “deeply rooted in this Nation’s history and tradition, and implicit in the concept of ordered liberty, such that neither lib- erty nor justice would exist if they were sacrificed.” Glucksberg , 521 U.S. at 721 (cleaned up). It is hard to imagine a right less amenable to sacrifice while liberty and justice still exist than a parent’s right to save her child’s life with well-established, evidence-based, non- *127 experimental medical treatment, subject to medically accepted standards and a physician’s independent examination and medical judgment. And what are liberty and justice if not the right of a parent to protect her child from death with a non-experimental medical treatment, based on a physician’s recommendation?
Yet the panel opinion and the Lagoa Statement wave off Par- ham for six reasons. None stands up to examination.
First
, the panel opinion dismisses
Parham
as a procedural-
due-process case, not a substantive-due-process case.
See Eknes-
Tucker II
,
Second
, the Lagoa Statement asserts that a later case under-
mined
Parham
’s clear application here. Lagoa St. at 22 (citing
Cru-
zan ex rel. Cruzan v. Dir., Mo. Dep’t of Health
,
In support of its (mistaken) contention, the Lagoa State-
ment quotes
Cruzan
’s remark,
id.
at 22–23, referring to
Parham
, that
the petitioners there sought “to turn a decision which allowed a
State to rely on family decisionmaking into a constitutional re-
quirement that the State recognize such decisionmaking.”
Cruzan
,
In
Cruzan
, the parents of an adult woman who was injured
in a car accident and had “virtually no chance of regaining her men-
tal faculties” sought, on the woman’s behalf, to terminate her nu-
trition and hydration.
In the Supreme Court, the parents argued that the state “must accept the ‘substituted judgment’ of close family members even in the absence of substantial proof that their views reflect the views of the patient.” Id. at 285–86. The Supreme Court rejected that because, among other reasons, “[a] State is entitled to guard against potential abuses” by family members who “will not act to protect a patient.” Id. at 281, 286. Only in that context did the Court dismiss the family members’ Parham argument as “seek[ing] to turn a decision which allowed a State to rely on family deci- sionmaking into a constitutional requirement that the State recog- nize such decisionmaking.” Id. at 286.
In context, Cruzan bears no resemblance to this case. So it makes no difference that “ Cruzan did not distinguish Parham on any of the grounds” I point out. Lagoa St. at 23.
To start,
Cruzan
concerned close family members’ rights to
direct an
adult’s
medical care, not parental rights concerning a mi-
nor child. But
Parham
did not purport to recognize a fundamental
right of family members of an adult. Indeed, the
Parham
right lives
under the more general, “perhaps . . . oldest of the fundamental
liberty interests recognized by th[e] Court”: “the fundamental right
of parents to make decisions concerning the care, custody, and con-
trol of their children.”
Troxel
,
And Cruzan involved the right to withdraw medical treat- ment to allow the adult patient to die, not the parents’ right to di- rect potentially life-saving medical treatment.
Given these two significant differences, the Court concluded
that
Parham
did not control
Cruzan
’s novel facts—the petitioners’
asserted right to direct the withdrawal of their adult relative’s med-
ical care. But the Court did not purport to limit
Parham
’s funda-
mental right of a parent to direct that her child receive well-estab-
lished, evidence-based, non-experimental medical treatment, sub-
ject to medically accepted standards and a physician’s independent
examination and medical judgment.
See Parham
,
So it is no answer that Parham did not elevate familial deci- sion-making—by any close family member—in all circumstances. Here, Parham directly applies. And “when a precedent of the Su- preme Court has direct application, we must follow it.” United States v. Johnson , 921 F.3d 991, 1001 (11th Cir. 2019) (en banc) (cleaned up). We cannot, as the Lagoa Statement does, sidestep it.
Third
, the panel opinion says, “
Parham
does not at all suggest
that parents have a fundamental right to direct a particular medical
treatment for their child that is prohibited by state law.”
Eknes-
Tucker II
,
Nowhere did Parham purport to qualify its right with a state- law limitation. Nor would that limitation make sense, or funda- mental rights would be meaningless. If the Lagoa Statement were correct, any “fundamental right” would evaporate instantly upon a state’s banning of a particular treatment. That is, it would enjoy no protection. And what’s a fundamental right if the state can ab- rogate it at will?
The Lagoa Statement’s contrary contention elementally misunderstands the nature of a fundamental right. Constitutional protections are not so susceptible to state-law abrogation.
Fourth
, the Lagoa Statement invokes Circuit precedent to
suggest we have somehow cabined
Parham
’s right. Lagoa St. at 12–
14 (first citing
Doe v. Moore
,
In Doe , the plaintiffs made only “broad claims that the [chal- lenged law] infringe[d] their liberty and privacy interests.” 410 F.3d at 1343. We rejected a “broad category” of due-process rights for which “any alleged infringement on privacy and liberty will be *132 subject to substantive due process protection.” Id. at 1344. And because the plaintiffs’ asserted right was so “broad,” we had “to de- fine the scope of the claimed fundamental right” in the first in- stance. Id. By contrast, the Parents do not rely on a “broad cate- gory.” Rather, they rely on the careful description of the right that Parham has already recognized.
Morrissey
is similarly uninstructive. There, the plaintiff
claimed to assert the “fundamental right to procreate,” but he re-
ally asserted a right to enlist the state to assist him in procreation—
by providing a tax write-off for
in vitro
fertilization.
See
871 F.3d at
1269. The plaintiff there relied on
Skinner v. Oklahoma
,
Fifth
, the Lagoa Statement points to yet another inapposite
case—this time from outside our Circuit:
Abigail Alliance for Better
Access to Developmental Drugs v. von Eschenbach
,
Of course, Abigail Alliance does not bind us.
But even if it did, the claimed right in Abigail Alliance was different from the right Parham recognizes and the Parents here in- voke. In Abigail Alliance , the terminally ill patients asserted the right to use experimental new drugs that the U.S. Food and Drug Administration (“FDA”) had not approved for any use, that were not widely accepted, and that were not the standard of medical care. See id. at 700. In contrast, the fundamental right Parham rec- ognizes is parents’ right to direct the care of their children with well-established, evidence-based, non-experimental medical treat- ment, subject to medically accepted standards and a physician’s in- dependent examination and medical judgment.
And as a factual matter, the medical treatment here differs
from those at issue in
Abigail Alliance
. The district court here found
that transitioning medications (1) were not new drugs, as “medical
*134
providers have used transitioning medications for decades to treat
medical conditions other than gender dysphoria”; (2) Alabama
“produce[d] no credible evidence to show that transitioning medi-
cations are ‘experimental’”; (3) “the uncontradicted record evi-
dence is that at least twenty-two major medical associations in the
United States endorse transitioning medications as well-estab-
lished, evidence-based treatments for gender dysphoria in minors”;
and (4) the use of transitioning medications to treat gender dyspho-
ria in minors is “subject to medically accepted standards.”
Eknes-
Tucker I
,
Plus, in pediatric medicine, off-label drug use [13] (such as using FDA-approved puberty blockers and hormones to treat severe gen- der dysphoria) is not “improper, illegal, contraindicated, or investi- gational.” 14 Kathleen A. Neville et al., Off-label Use of Drugs in Chil- dren , 133 Pediatrics 563, 563 (2014). Nor is it considered “experi- ment[al] or research.” Id. at 565. In fact, off-label medication use by minors is especially common and often necessary because an “overwhelming number of drugs” have no FDA-approved instruc- tions for use in pediatric patients. Id. at 563. That is so because the child patient population is “frequently excluded from clinical tri- als.” Furey & Wilkins, supra n.13, at 589. And even the Alabama legislature has recognized that “[o]ff-label use of an FDA-approved drug is legal when prescribed in a medically appropriate manner boys). See, e.g. , Garry L. Warne et al., Hormonal Therapies for Individuals with Intersex Conditions , 4 Treatments in Endocrinology 19, 19–29 (2012); Ronald S. Swerdloff et al., Gynecomastia: Etiology, Diagnosis, and Treatment (last updated Jan. 6, 2023), https://www.ncbi.nlm.nih.gov/books/NBK279105/ [https://perma.cc/EVU2-8C8H].
[13] “‘Off-label’ drug use commonly refers to prescribing currently available medication for an indication (disease or symptom) for which it has not re- ceived FDA approval. Off-label use also includes prescribing a drug for a dif- ferent population or age range than that in which it was clinically tested and using a different dosage or dosage form.” Katrina Furey & Kirsten Wilkins, Prescribing “Off-Label”: What Should a Physician Disclose? , 18 AMA J. Ethics 587, 588 (2016) (internal citations omitted).
[14] See also H. Christine Allen et al., Off-Label Medication Use in Children, More Common than We Think: A Systematic Review of the Literature , 111 J. Okla. State Med. Ass’n 776, 781 (2018).
and is often necessary to provide needed care.” A LA . C ODE § 27-1- 10.1(a)(5) (2022).
So neither Abigail Alliance ’s holding nor its reasoning carries persuasive weight here. Rather, Parham controls the analysis. And as I’ve explained, Parham recognizes the Parents’ asserted right as fundamental.
Sixth and finally, unable to show that Parham ’s right doesn’t remain intact, the Lagoa Statement tries to remove this case from Parham ’s reach by suggesting that gender-affirming treatment is not “medical care.” See Lagoa St. at 3–5. But the record evidence, the medical consensus, the district court’s factual findings, and common sense all rebut that. Under the leading authority—the WPATH Standards of Care—treatment “involv[es] holistic inter- and multidisciplinary care between endocrinology, surgery, voice and communication, primary care, reproductive health, sexual health and mental health,” including the provision of “hormone therapy.” [15] This treatment is indisputably “medical.” The Lagoa Statement can’t use a patently incorrect characterization to remove this case from Parham ’s reach.
So it pivots, arguing instead that whether gender-affirming
care qualifies as “life-saving” or even as “medical care” is itself a
“policy” question for the state.
See
Lagoa St. at 3–5. But that ma-
neuver fails just as certainly. For starters, Alabama does not as-
sert—nor could it—that the Act does not prohibit “medical” care.
*137
And no one could rationally claim that medical care that reduces
rates of “suicidality” (as well as “self-harm”) is not “life-saving.”
Eknes-Tucker I
,
But more to the point, courts do not defer to the legislature
when the question is whether the conduct at issue falls within the
“the scope of [a plaintiff’s] constitutional rights.”
United States v.
Mills
,
It is very much the courts’ responsibility to assess whether
the state has proved that a treatment it seeks to regulate falls within
or outside the fundamental
Parham
category.
See, e.g.
,
United States
v. Stevens
,
In sum, Parham recognizes parents’ fundamental right to di- rect the medical care of their children with well-established, evi- dence-based, non-experimental medical treatment, subject to med- ically accepted standards and a physician’s independent examina- tion and medical judgment. And it’s the Lagoa Statement’s mach- inations to avoid being bound by Parham —not this dissent—that “mark out new terrain.” Lagoa St. at 23.
2. The panel opinion unjustifiably imposes an historical requirement that no modern medical treatment could sat- isfy.
Besides incorrectly sidelining
Parham
itself, the panel opin-
ion and the Lagoa Statement mischaracterize the fundamental
right that
Parham
recognizes. First off, the panel opinion and the
Lagoa Statement hyper-narrowly describe the asserted right the
Parents invoke here as the parents’ “right to treat one’s children
with transitioning medications subject to medically accepted stand-
ards.”
[16]
Eknes-Tucker II
,
Then, the panel opinion imposes the 1868 Methodology on
our jurisprudence governing parents’ fundamental right to direct
the medical care of their children.
See id.
at 1220–21. It criticizes
the district-court order for failing to “feature any discussion of the
history of the use of [transitioning medications] or otherwise ex-
plain
how that history informs the meaning of the Fourteenth Amend-
ment at the time it was ratified—July 9, 1868
.”
Id.
at 1221 (emphasis
added);
see also
Lagoa St. at 25–26. Finding no “historical analysis
specifically tied to [transitioning medications],” the panel opinion
declares parents have no “fundamental right to treat one’s children
with transitioning medications subject to medically accepted stand-
ards.”
Eknes-Tucker II
,
Two responses: first, a by-now old refrain—in
Parham
, the
Supreme Court already recognized the fundamental right at issue
treat their children with transitioning medications subject to medically ac-
cepted standards” only as the natural conclusion of its findings that transition-
ing medications satisfied
Parham
’s categorical requirements.
Eknes-Tucker I
,
(parents’ fundamental right to direct that their child receive well- established, evidence-based, non-experimental medical treatment, subject to medically accepted standards and a physician’s independ- ent examination and medical judgment). So our recognition of that right is not optional. For that reason, retreading history to show that Parham ’s right is, in fact, fundamental is neither neces- sary nor appropriate.
And second, as I’ve explained, it’s impossible for any histori- cal discussion of transitioning medications to have “inform[ed] the meaning of the Fourteenth Amendment at the time it was ratified,” id. , because medicine hadn’t discovered transitioning medications as of July 9, 1868, and didn’t do so until the twentieth century. The same is, of course, true of all modern medicine. So under the panel opinion’s framing of the asserted right—by specific medical treat- ment sought—parents have only the fundamental right to direct their child’s medical treatment with those treatments existing as of July 9, 1868.
Obviously, the 1868 Methodology is wrong. The Framers of
the Fourteenth Amendment did not forever tie parents’ fundamen-
tal right to direct the medical care of their children to nineteenth-
century medical treatments. And we don’t assess a parent’s funda-
mental right to direct her child’s medical care treatment by treat-
ment.
Cf. Vidal v. Elster
,
Rather, we view constitutional rights at a high enough level
of generality to ensure “the basic principles” that define our rights
“do not vary” in the face of “ever-advancing technology.”
Moody v.
NetChoice
, LLC,
The Lagoa Statement tries to run from the consequences of the panel opinion’s plain language imposing the 1868 Methodol- ogy. According to the Lagoa Statement’s retcon version of the panel opinion, the panel opinion merely “notes the absence of any historical support for the position reached by the district court” be- cause whether parents have the fundamental right to direct that their children receive medical treatments in existence after 1868 “was not before the panel.” Lagoa St. at 25 n.13.
I can understand why the Lagoa Statement would like to for-
get what the panel opinion expressly says—(1) that we must char-
acterize the right at issue as the parent’s right to direct the medical
treatment of their child with the specific treatment at issue— here,
transitioning medications,
Eknes-Tucker II
,
But whether the Lagoa Statement owns up to it or not, the panel opinion’s express statements and reasoning undeniably mean that, to be covered by the parents’ fundamental right to direct their child’s medical care, a medical treatment must have existed as of *143 1868. Even the Lagoa Statement offers no suggestion as to how a medical treatment could have “inform[ed] the meaning of the Fourteenth Amendment at the time it was ratified” if that treat- ment did not yet exist then. The 1868 Methodology is so clearly wrong that its own author now denies the words she wrote. Un- fortunately, it can’t be undone that easily. Only this Court sitting en banc (or the Supreme Court) can clean up the panel opinion’s mess. But because we will not rehear this case en banc, the 1868 Methodology now governs all of us in the states of Florida, Geor- gia, and Alabama—despite its author’s attempt to disavow it.
The Lagoa Statement also tethers the 1868 Methodology’s required analysis to adults ’ historical access to the treatment at is- sue. See id. at 27. But that argument fails for the same reason the panel opinion and the Lagoa Statement’s attempts to impose a treatment-by-treatment framework fail: Parham has already estab- lished that we don’t evaluate a parent’s fundamental right to direct the medical care of their child treatment by treatment. Rather, un- der Parham , we ask only whether a given treatment falls into the category of well-established, evidence-based, non-experimental medical treatments, subject to medically accepted standards and a physician’s independent examination and medical judgment. And if it does, that is the end of the matter because Parham recognizes a parent’s fundamental right to direct such a treatment for their child’s medical care.
Our “venerable and accepted tradition” of parental due-pro-
cess rights, including
Parham
’s carefully described right, ‘“is not to
*144
be laid on the examining table and scrutinized for its conformity to
some abstract principle’ of ‘adjudication devised by this Court.’”
See United States v. Rahimi
,
B. The use of transitioning medications is a well-established, evi-
dence-based, non-experimental medical treatment, subject to med- ically accepted standards and a physician’s independent examina- tion and medical judgment.
To put the district court’s decision in context, I note that in
the United States, roughly 300,000 thirteen-to-seventeen-year-olds
identify as transgender.
[18]
Some of those teenagers—like Plaintiff
Megan Poe’s daughter—experience severe mental-health effects—
including suicidal thoughts—associated with gender dysphoria.
See
Eknes-Tucker I
,
Some of these kids inevitably will succeed. That makes ef- fective treatment of severe gender dysphoria critical.
Given these potentially devastating effects of severe gender
dysphoria, “[i]n some cases, physicians treat gender dysphoria in
minors with . . . puberty blockers” to delay the onset of puberty
while the minor socially transitions or decides whether to do so.
Eknes-Tucker I,
As I’ve recounted, the district court’s factual findings under- score the widespread medical consensus that using transitioning medications to treat severe gender dysphoria in minors is a well- established, evidence-based treatment that follows medical stand- ards. Yet the panel opinion and Lagoa Statement focus myopically on the treatment’s potential (and undisputed) risks.
To be sure, and as the district court recognized and the
WPATH Standards of Care acknowledge, transitioning medica-
tions—likely nearly every medical treatment—are not without
risks. But as the Supreme Court recognized, and as the district
court found, the fact that a treatment “‘involves risks does not au-
tomatically transfer the power’ to choose that medication ‘from
the parents to some agency or officer of the state.’”
Eknes-Tucker I
,
The Lagoa Statement now questions that factual finding and others. See , e.g. , Lagoa St. at 43 (“Alabama provided significant evi- dence that the medications covered by the Act are dangerous and ineffective.”). But the panel opinion never found even one of the district court’s factual findings to be clearly erroneous. And given that we have denied en banc rehearing, the Lagoa Statement can’t do that now. That is improper.
Worse still, the Lagoa Statement relies on unvetted material from outside the factual record to try to justify its newfound con- clusion that the district court clearly erred. [20] Ours is an adversarial *147 system of justice, so if the Lagoa Statement wishes to rely on these materials, the parties must receive the opportunity to test them, and the district court must determine their admissibility [21] and denies climate change and refers to mask-wearers as “narcissists and psycho- paths.” Environmental Progress, Escape the Woke Matrix (last visited Aug. 19, 2024), https://environmentalprogress.org/escape-the-woke-matrix [https://perma.cc/84D8-89SA]. Environmental Progress does not perform medical research. And a review of the purported WPATH communications does not reveal why the Lagoa Statement asserts that they “impugn[] the cred- ibility of the [WPATH].” Lagoa St. at 5. Nor does it suggest that WPATH officials are “mischaracterizing and ignoring information about” transitioning medications. Id. at 5. To the contrary, the WPATH Standards of Care ex- pressly state that a “careful discussion” of “all potential risks and benefits” is a “necessary step in the informed consent/assent process.” WPATH Standards, supra n.9, at S61–63. And they also caution that the parent or “legal guardian is integral to the informed consent process.” See id. But in any case, the bot- tom line is that fact-finding is the district court’s job, not ours—and certainly not in a statement respecting the denial of en banc rehearing.
[21] For example, the Lagoa Statement cherry-picks quotations from the WPATH Files “report” that don’t accurately characterize the working group’s conver- sation as a whole. See Lagoa St. at 4–5, 47–49. And beyond that, it’s not even clear that the “report” includes or accurately summarizes the complete source material, see F ED . R. E VID . 106, 1006, or satisfies any of the hearsay exceptions that secure the reliability of out-of-court statements, id. 801–03. If the Lagoa Statement offers the “report” to impeach WPATH’s “genuine[ness],” Lagoa St. at 48, the declarants normally must have a chance to explain or deny the statements, F ED . R. E VID . 613. Of course, trial courts are in the best position to consider these evidentiary questions in the first instance—a point that the Lagoa Statement’s uncritical use of out-of-court statements aptly shows. *148 relevance. [22] And it must make factual findings about their credibil- ity. None of those things occurred here.
Not only that, but the panel opinion and Lagoa Statement effectively substitute their medical judgment for that of the major medical organizations, not to mention the individual clinicians pre- scribing transitioning medications. Medical professionals have ex- tensive scientific and clinical training. Doctors attend four years of medical school, three to seven years of residency, potential fellow- ships or research positions, and beyond. And then they practice medicine every day.
We, on the other hand, receive no medical training in law school. We don’t go through residencies or fellowships. We don’t engage in medical research. And we don’t practice medicine at all. In fact, many of us went into the law because, among other rea- sons, we weren’t good at math or science. Given our lack of med- ical expertise, we have no business overriding either the medical consensus that transitioning medications are safe and efficacious or clinicians’ ability to develop individualized treatment plans that fol- low the governing standards of care. “The Constitution’s con- tours” may not be “shaped by expert opinion,” Lagoa St. at 27, but medical practice certainly is.
And to the extent that some “particular medical treatments
[may] reasonably [be] prohibited by the Government,”
Abigail All.
,
like the Act, and 5% had actually moved out of state because of such legisla-
tion.
Id.
at 23. All three states in this Circuit—Alabama, Florida, and Geor-
gia—are among the top ten states that respondents reported leaving.
Id.
So if
extra-record sources are considered, the parties must have the chance to pre-
sent whatever other sources they think relevant. And they should have the
chance to show why any new proposed sources should not be relied on.
*150
Because parents have a fundamental right to direct that their children receive well-established, evidence-based, non-experi- mental medical treatment, subject to medically accepted standards and a physician’s independent examination and medical judgment, see Parham , 442 U.S. at 602, and transitioning medications meet those criteria, the Parents have alleged a colorable substantive-due- process claim.
*151 C. It is substantially likely that the Act does not survive strict scru-
tiny
.
Having carefully identified the right at stake here as funda-
mental, we must apply strict scrutiny to the Act. That means the
Act must be “narrowly tailored” to achieve “a compelling state in-
terest.”
Reno
,
As I’ve noted, the district court rejected each of the State’s
purported justifications for the Act. The district court found that
the State “fail[ed] to produce evidence showing that transitioning
medications jeopardize the health and safety of minors suffering
from gender dysphoria.”
Eknes-Tucker I
,
But even if the State’s “speculative” justifications were suffi- ciently “compelling,” the Act is not narrowly tailored to achieve those state interests. A categorical ban on gender-affirming medi- cal care for all minors is hopelessly overbroad. If the State is con- cerned with minors’ health and safety or with the rigor of the ap- proval process for treatment, it can mandate medical protocols in line with the WPATH Standards of Care and other guidelines. And if it fears that some healthcare professionals have committed mal- practice by failing to obtain informed consent or otherwise comply with the governing standards of care, the State can take tailored *152 enforcement action. Similarly, if a State is worried about minors’ ability to consent, see Lagoa St. at 45–46, it can require parental con- sent or otherwise mandate informed-consent procedures like the WPATH Standards of Care require.
In fact, the district court cited record evidence of other less
restrictive alternatives, including “allow[ing] minors to take transi-
tioning medications in exceptional circumstances on a case-by-case
basis.”
Eknes-Tucker I
,
That does not mean that a state could never prohibit a par- ticular medical treatment for minors. If a state sought to outlaw a course of treatment that was not medically accepted or efficacious and that posed serious risks without benefits, that prohibition would likely clear even strict scrutiny. But that is not the case here. To the contrary, the record shows that denying gender-affirming medical care to transgender minors with severe gender dysphoria is more likely to “jeopardize [their] health or safety,” id. at 1145, by compromising their mental health and putting them at increased risk of suicide.
In sum, when we properly frame the parents’ right at issue and apply strict scrutiny, the Parents are substantially likely to suc- ceed on their claim that the Act violates the Fourteenth Amend- ment’s substantive-due-process guarantee. The panel opinion’s *153 contrary conclusion is not only legally wrong but dangerous for minors with severe gender dysphoria and their parents—and for every parent seeking modern medical care for their child in Ala- bama, Florida, or Georgia.
III. The panel opinion wrongly concludes that the Minors are not substantially likely to succeed on the merits of their equal-protection claim.
The Fourteenth Amendment’s Equal Protection Clause
guarantees that no state shall “deny to any person within its juris-
diction the equal protection of the laws.” U.S. Const. amend. XIV,
§ 1. To evaluate whether a law violates the Equal Protection
Clause, “we apply different levels of scrutiny to different types of
classifications.”
Clark v. Jeter
,
For classifications that disadvantage a “suspect class,” we ap-
ply strict scrutiny.
Mass. Bd. of Retirement v. Murgia
,
The second, or middle, tier of review is “intermediate scru-
tiny.”
Clark
,
Third, if a classification qualifies as neither suspect nor quasi-
suspect under the Equal Protection Clause, we apply rational-basis
review.
See Clark
,
As I explain below, the Act discriminates based on two quasi- suspect classifications: sex and transgender status. So either classi- fication requires us to apply intermediate scrutiny. When we do that, the Act cannot survive.
But the panel opinion fails to recognize as quasi-suspect the classifications the Act makes. Instead, it incorrectly applies ra- tional-basis review to uphold the Act.
Section A shows that the Act relies on sex-based classifica- tions. Section B explains that the Act also employs the quasi-sus- pect classification of transgender status. Because the Act uses quasi-suspect classifications, Section C then applies intermediate scrutiny to the Act.
A. The panel opinion fails to recognize that the Act classifies based on
sex.
The Act prohibits the prescription or administration of tran- sitioning medications “for the purpose of attempting to alter the appearance of or affirm the minor’s perception of his or her gender or sex, if that appearance or perception is inconsistent with the mi- nor’s sex.” S.B. 184 § 4(a). In its operation, the Act classifies based on sex in three ways. First, the Act restricts minors’ access to pu- berty blockers and hormones based on the minors’ sex. Second, the Act relies on gender stereotyping. And third, the Act discrimi- nates against transgender individuals because they are transgender, and that is necessarily discrimination because of sex.
First , the Act conditions minors’ access to puberty blockers and hormone therapy on their sex. The upshot of the Act, then, is *156 that transgender boys and girls are forced to conform to Alabama’s view of what birth-assigned girls and boys, respectively, should look like at their ages.
For example, suppose a transgender girl (birth-assigned
boy), after consulting her parents and doctors, decides to take es-
trogen so her biological development reflects her gender identity.
Under the Act, she cannot access that medication. But a cisgender
girl (birth-assigned girl) with an estrogen deficiency who is pre-
scribed estrogen for the same reason—so her biological develop-
ment matches her gender identity—can. Both seek to alter their
appearance to match their gender identities, but only the
transgender girl is prohibited from using the medication because
the desired appearance “is inconsistent with the minor’s sex” as as-
signed at birth. S.B. 184 § 4(b). And a medical professional cannot
determine whether the Act prohibits such a treatment “without in-
quiring into a patient’s sex assigned at birth and comparing it to
their gender identity.”
See Kadel v. Folwell
,
In other words, but for the Minors’ birth-assigned sex, they
could access the same treatment to delay puberty or to ensure that
their appearances reflect their gender identities.
See Brandt ex rel.
Brandt v. Rutledge
, 47 F.4th 661, 669–70 (8th Cir. 2022). So “[s]ex
plays a necessary and undisguisable role” in the Act’s operation.
Bostock
, 590 U.S. at 652. That is “textbook sex discrimination.”
Kadel
,
The panel opinion seeks to avoid this straightforward con- clusion by asserting that the Act “applies equally to both sexes.” Eknes-Tucker II , 80 F.4th at 1228. But that the Act discriminates against both transgender boys and transgender girls based on sex does not change the fact that the Act discriminates based on sex.
In fact, the Supreme Court rejected a variety of that same
argument in
Bostock
. There, the Court considered whether, under
Title VII, an employer could lawfully “fire[] a woman . . . because
she is insufficiently feminine and also fire[] a man . . . for being in-
sufficiently masculine”—that is, whether the employer could law-
fully discriminate, “more or less equally,” against both men and
women under Title VII.
Bostock
,
True,
Bostock
dealt with Title VII, not the Fourteenth
Amendment. But
Bostock
concluded that discriminating against
both men and women is no defense to Title VII because Title VII
prohibits discrimination against “individual[s],” rather than
“against women [or men] as a class.”
See id.
at 658–59. So too with
the Fourteenth Amendment, which guarantees that “[n]o State
shall . . . deny
to any person
within its jurisdiction the equal protec-
tion of the laws.” U.S. Const. amend. XIV, § 1 (emphasis added).
Without citation to any authority, the panel opinion also
contends that the Act does not discriminate based on sex because
*158
it “refers to sex only because the medical procedures that it regu-
lates . . . are themselves sex-based.”
Eknes-Tucker II
, 80 F.4th at
1228. This attempt to avoid the Act’s sex-based classifications fails.
First, the Act refers to sex apart from the medical procedures when
it restricts use of puberty blockers and hormone therapy for only
those minors trying to change their appearance in a way “incon-
sistent with their sex.” S.B. 184 § 4(b). But second, even if we ac-
cept the panel opinion’s incorrect premise, the mere fact that a law
refers to sex-based medical procedures does not somehow insulate
it from equal-protection scrutiny. As the Act shows, a law can both
“refer[] to sex only because the medical procedures that it regulates
. . . are themselves sex-based,”
Eknes-Tucker II
,
Similarly, the panel opinion invokes Dobbs ’s pronouncement that “the regulation of a medical procedure that only one sex can undergo does not trigger heightened constitutional scrutiny unless the regulation is a mere pretext designed to effect an invidious dis- crimination against members of one sex or the other.” Id. at 1229 (quoting Dobbs v. Jackson Women’s Health Org. , 597 U.S. 215, 236 (2022)) (cleaned up). This argument fails.
Unlike abortion, treatment with transitioning medications is not “a medical procedure that only one sex can undergo,” id. Both boys and girls have sex hormones. And as they have for decades for medical conditions other than gender dysphoria, doctors can pre- scribe puberty blockers and hormones for both boys and girls. In *159 fact, both male and female bodies produce and use both testos- terone and estrogen, though in different quantities. [24] That the hor- mones doctors prescribe for birth-assigned boys and girls may not be precisely the same does not somehow make the administration of puberty blockers and hormone therapy “a medical procedure that only one sex can undergo,” id .
Second
, the Act employs sex-based classifications through its
use of gender stereotypes. Gender stereotypes “presume that men
and women’s appearance and behavior will be determined by their
sex.”
Brumby
,
The Lagoa Statement’s attempts to pin Alabama’s discrimi- nation on “physical differences” falls short. Lagoa St. at 37. In fact, the very case it cites, United States v. Virginia , 518 U.S. 515, 533 (1996), makes plain its error. There, the Virginia Military Institute argued it could exclude women because the “psychological and so- ciological differences” between men and women prevented women from succeeding in its strenuous curriculum. Id. at 549. Virginia proffered that those biological differences were “real” and “not stereotypes.” Id. But the Court rejected that argument. Alt- hough Virginia identified some physical differences, the Court ex- plained, its “generalizations” from those differences were stereo- types about “the way most women are” or “what is appropriate for most women.” Id. at 550 (emphasis omitted).
The Lagoa Statement contains the same flaw. Sure, § 4(a) mentions “physical differences” between boys and girls. But as I’ve noted, it recognizes those differences only because they conform to Alabama’s view of “what is appropriate” for boys and girls, id . [25]
Third
, the Act classifies based on transgender status and gen-
der non-conformity, which the Supreme Court and we have found
indirectly discriminates based on sex.
See Bostock
,
Again, the Act prohibits the use of transitioning medications
only if prescribed to “affirm the minor’s perception of his or her
gender or sex, if that appearance . . . is inconsistent with the mi-
nor’s sex.” S.B. 184 § 4(a). In other words, the Act proscribes tran-
sitioning medications for transgender minors only.
See Eknes-Tucker
I
,
As the Supreme Court explained in
Bostock
, “it is impossible
to discriminate against a person for being . . . transgender without
discriminating against that individual based on sex.”
statutory distinction in presumed parentage. Id. In contrast, the Lagoa State- ment identifies a biological difference but does not explain how or why that difference “substantially relate[s]” to Alabama’s “important governmental in- terest.” Id.
The Lagoa Statement aims to circumvent this precedent by
conclusorily stating that “[b]ecause the language of the Equal Pro-
tection Clause does not resemble the language of Title VII,
Bos-
tock
’s reasoning does not apply here.” Lagoa St. at 36;
see also Eknes-
Tucker II
,
Rather, the Lagoa Statement blindly pulls out-of-context
quotations from Justice Gorsuch’s concurrence in
Students for Fair
Admissions, Inc. v. President & Fellows of Harvard College
,
So whether an employee is fired for being transgender, or a teenager is denied healthcare for being transgender, “[s]ex plays a necessary and undisguisable role in the decision.” Bostock , 590 U.S. at 652. Indeed, it makes little sense to conclude that discrimination against transgender persons “necessarily and intentionally applies sex-based rules,” id. at 667, in the Title VII context but has no rela- tion to sex in the Equal Protection Clause context. See Kadel , 100 F.4th at 180–81 (Richardson, J., dissenting) (for both Title VII and the Equal Protection Clause, “ Bostock tells us that to discriminate on the basis of [transgender status] is necessarily to discriminate ‘because of ’ sex”).
After all, the Court did not say that “transgender status [is]
inextricably bound up with sex” in the workplace alone.
See Bos-
tock
,
Plus,
Bostock
is not the only precedent on point here.
Brumby
—which concerned the Fourteenth Amendment’s Equal
Protection Clause and which we decided before
Bostock
—also con-
trols this analysis. In
Brumby
, we held that “discriminating against
[a transgender person] on the basis of his or her gender non-
*164
conformity constitutes sex-based discrimination under the Equal
Protection Clause.”
The panel opinion tries to avoid this fact by cabining
Brumby
’s reading of the Fourteenth Amendment to “the context of
employment discrimination.”
See Eknes-Tucker II
,
Finally, the Lagoa Statement perpetuates the fiction that the
Act discriminates on the basis of “purpose,” not sex or transgender
*165
identity. Lagoa St. at 34–35. But in the context of this case, “dis-
criminating on the basis of [purpose]
is
discriminating on the basis
of gender identity and sex.”
Kadel
,
In short, Bostock and Brumby are binding precedents that show why the Minors have a substantial likelihood of success on the merits of their equal-protection claim. [26] B. The panel opinion fails to recognize that the Act classifies based
on transgender status, a quasi-suspect class in its own right for purposes of equal-protection analysis.
The previous section explains why the Act discriminates
based on sex. But the panel opinion also fails to recognize that
transgender status is itself a quasi-suspect classification.
See Eknes-
Tucker II
,
To be sure, a majority of this Court previously expressed
“grave ‘doubt’ that transgender persons constitute a quasi-suspect
class,”
Adams
,
First, transgender status is immutable, or, as we have defined it, “consistent[], insistent[], and persistent[].” See id. at 807. And those that take puberty blockers or gender-affirming hormones necessarily have a “consistent[], insistent[], and persistent[]” transgender identity. See id. That some individuals who experience some form of gender incongruence ultimately embrace their birth- assigned gender or detransition does not alter this reality because those individuals are not “transgender” as our precedent (and med- ical science) defines the term. See id.
Transgender status is also “distinguishing.” In fact, it’s a spe-
cific basis on which the Act distinguishes. The Act prohibits the use
of puberty blockers and hormone therapy only “for the purpose of
attempting to alter the appearance of or affirm the minor’s percep-
tion of his or her gender or sex, if that appearance or perception is
inconsistent with the minor’s sex,”—in other words, only when the
*167
minor is transgender.
See
S.B. 184 § 4(a). Contrary to the Lagoa
Statement’s assertions, the fact that a “wide spectrum” of non-bi-
nary individuals may identify as “transgender,” Lagoa St. at 40–41,
does not mean that it is not a “distinguishing” label. For instance,
a diverse group of individuals may identify with a particular race,
religion, or national origin, but precedent firmly establishes that
race, religion, and national origin are suspect classes.
See Clark
, 486
U.S. at 461;
City of New Orleans v. Dukes
,
Second, as the Fourth Circuit has observed, “there is no
doubt that transgender individuals historically have been subjected
to discrimination on the basis of their gender identity, including
high rates of violence and discrimination in education, employ-
ment, housing, and healthcare access.”
Grimm v. Gloucester Cnty.
Sch. Bd.
,
Third, transgender persons are no doubt a minority lacking
in political power. “Even when we take into account the small pro-
portion of the population transgender individuals comprise, they
are underrepresented in political and judicial office nationwide.”
Adams
,
Fourth and finally, transgender status bears no “relation to
ability to perform or contribute to society.”
Grimm
,
So all four factors show that transgender persons are a quasi-
suspect class, and intermediate scrutiny applies.
See Adams
, 57 F.4th
at 848–50 ( J. Pryor, J., dissenting);
Grimm
,
C. It is substantially likely that the Act fails intermediate scrutiny.
Because intermediate scrutiny applies, we ask whether the
Act serves “important governmental objectives” and employs
means “substantially related to the achievement of those objec-
tives.”
Miss. Univ.
,
Alabama invokes the interest of protecting children’s safety.
And of course, I agree that “[i]t is indisputable ‘that a State’s inter-
est in safeguarding the physical and psychological well-being of a
minor is compelling.’”
Otto v. City of Boca Raton
,
Just as it is substantially likely that the Act cannot survive strict scrutiny, it is substantially likely that the Act fails intermediate scrutiny as well. Again, the district court found that gender-affirm- ing medical care is not “experimental”—to the contrary, it is widely-endorsed, “well-established, evidence-based treatment[].” Eknes-Tucker I , 603 F. Supp. 3d at 1145. So Alabama’s interest in “safeguarding the physical and psychological well-being,” Otto , 981 F.3d at 868, of its minors does not itself permit Alabama to outlaw transitioning medications on the basis of sex or transgender status. In fact, across-the-board prohibition of access to transitioning med- ications itself compromises the “physical and psychological well- being” of minors with severe gender dysphoria—putting them at greater risk of suicidality and depression. [31]
What’s more, the Act permits the use of the very puberty blockers and hormones it outlaws for treatment of gender dyspho- ria in Minors, for treatment of minors with other conditions. The continued availability of this medication to cisgender minors un- dercuts the State’s purported safety rationale and renders the Act over- and under-inclusive. When we account for the State’s as- serted rationale, the Act is over-inclusive, as it prohibits gender- *172 affirming hormone therapy for all transgender minors regardless of their medical circumstances. And it is under-inclusive because it does not altogether bar the medications. Rather, it concedes that puberty blockers and hormone therapy are safe and medically ad- visable in other circumstances. Simply put, the Act’s ends and means are not substantially related, and the Minors are substan- tially likely to show that it fails intermediate scrutiny.
Because the Act unlawfully discriminates against the Minors based on their sex and transgender status, it must satisfy a more exacting standard than rational-basis review. The panel opinion’s contrary conclusion essentially rubber-stamps the Act’s denial of healthcare to transgender minors despite the State’s failure to meet its burden. The consequences will be profound.
IV. The panel opinion jettisons precedent to wrongly conclude that the Parents and Minors are not substantially likely to show that Alabama’s law violates two different constitutional rights: parents’ fundamental right to direct their children’s medical treatment and all individuals’ right to equal protection regardless of birth-as- signed sex or gender conformity. These legal and constitutional er- rors are more than academic. They sanction the denial of well- established, medically accepted treatment and leave parents help- less to prevent life-threatening harm. Neither precedent nor the record supports that result. Worst of all, it will needlessly cause parents and their children in the state of Alabama to suffer griev- ously.
I respectfully dissent from the denial of rehearing en banc.
Notes
[1] See, e.g. , Appendix A (KathyGrace Duncan), Appendix B (Carol Frietas), Ap- pendix C (Corinna Cohn). One of the dissents argues that we should disregard Wright’s testimony and the testimonies of Duncan, Frietas, and Cohn because all of them were at least eighteen years old when they started to medically transition and because “their ‘treatment’ did not follow WPATH Standards of Care.” Rosenbaum Dis. Op. at 10–11, 10 n.8. But that is not a reason to dis- regard their testimony, which demonstrates that those who are eighteen or older may fail to understand the dangerous, long-term effects cross-sex hor- mones and puberty blockers can have. If anything, these testimonies show why a legislative body may choose to restrict the use of these drugs by minors.
[2] The Cass Review, Independent review of gender identity services for children and young people (2024), https://cass.independent-review.uk/wp-content/up- loads/2024/04/CassReview_Final.pdf [https://perma.cc/9F73-D7BW] (hereinafter, “The Cass Review”).
[3] Clinical Policy: Puberty suppressing hormones (PSH) for children and young people who have gender incongruence/gender dypsphoria [1927] , Nat’l Health Serv., Eng. (Mar. 12, 2024), https://www.england.nhs.uk/wp-content/up- loads/2024/03/clinical-commissioning-policy-gender-affirming-hormones- v2.pdf [https://perma.cc/383H-LBVX] (hereinafter, “NHS Clinical Policy”).
[4] Mia Hughes, The WPATH Files , Environmental Progress (2024), https://static1.squarespace.com/static/56a45d683b0be33df885def6/t/65ea1 c1ea42ff5250c88a2f5/1709841455308/WPATH+Report+and+Files%28N%2 9.pdf [https://perma.cc/5HLY-TSUR] (hereinafter, “The WPATH Files”).
[5] Supraphysiologic means of or pertaining to an amount “greater than nor- See Supraphysiologic , Merriam-Webster , mally present in the body.” https://www.merriam-webster.com/medical/supraphysiological [https://perma.cc/QW8K-882J].
[6] Section 4 also forbids performing surgeries that sterilize, performing surger- ies that “artificially construct tissue with the appearance of genitalia that differs from the individual’s sex,” and removing “any healthy or non-diseased body part or tissue, except for a male circumcision.” Act § 4(a)(4)–(6). Plaintiffs originally challenged these portions of the Act also, but represented at the be- ginning of the preliminary-injunction hearing below that they were no longer seeking a preliminary injunction with respect to them. See Eknes-Tucker I , 603 F. Supp. 3d at 1139 n.5.
[7] These disorders include: (1)“[a]n individual born with external biological sex characteristics that are irresolvably ambiguous, including an individual born with 46 XX chromosomes with virilization, 46 XY chromosomes with under virilization, or having both ovarian and testicular tissue”; and (2) “[a]n individ- ual whom a physician has otherwise diagnosed with a disorder of sexual de- velopment, in which the physician has determined through genetic or
[9] As I discuss below, even if we were to accept the framing offered by either
Judge Jordan or Judge Rosenbaum, both still fail to “engage[] in a careful anal-
ysis of the history of the right at issue.”
Dobbs
,
[10] In
Muñoz
, the respondent invoked the “fundamental right of marriage,” but
the Court pushed further, concluding that the respondent actually “claim[ed]
something distinct: the right to reside with her noncitizen spouse in the United
States.”
[11] Judge Rosenbaum states that this analysis “elementally misunderstands the
nature of a fundamental right,” as “[c]onstitutional protections are not so sus-
ceptible to state-law abrogation.” Rosenbaum Dis. Op. at 24;
see also
Jordan
Dis. Op. at 23–25. In the abstract, she is of course correct that a state law
cannot trump an individual right afforded by the federal constitution. But
here, we are tasked with the antecedent question: whether the Parent Plain-
tiffs are substantially likely to show that they have such a right in the first place.
To do so, we must consult text, history, and tradition, as informed by binding
precedent, to determine whether the Due Process Clause affords such a right
and strips Alabama of the authority to enforce the Act.
See United States v.
Comstock
,
[12] This Court’s decisions similarly provide no support for the understanding of the Due Process Clause shared by Judges Jordan and Rosenbaum, the district
[13] A word about the so-called “1868 Methodology.” See Rosenbaum Dis. Op. at 1–2, 32–37. Judge Rosenbaum mischaracterizes the panel opinion as con- cluding that parents have the fundamental right to direct that their children receive “medical treatments in existence as of 1868.” Id. at 1. That issue, of course, was not before the panel. And the panel opinion merely notes the absence of any historical support for the position reached by the district court—a deficiency not cured on appeal.
[14] Indeed, elsewhere in its order, the district court recognized that “transition-
ing medications” come with “[k]nown risks,” including “loss of fertility and
sexual function.”
Eknes-Tucker I
,
[15] For example, studies suggest that significant health risks may stem from the use of these medications, including sterility, sexual dysfunction, lower bone density, high blood pressure, breast cancer, liver disease, cardiovascular dis- ease, and weight gain.
[16] NHS has also placed severe restrictions on “gender affirming hormones,” allowing for their use only after a child has turned sixteen and meets several other criteria. See Prescribing of Gender Affirming Hormones (masculinising or fem- inising hormones) as part of the Children and Young People’s Gender Service , Nat’l Health Serv., Eng., (Mar. 21, 2024), https://www.england.nhs.uk/wp-con- tent/uploads/2024/03/clinical-commissioning-policy-prescribing-of-gender- affirming-hormones.pdf [https://perma.cc/Q2TX-5KWP].
[17] As the Fifth Circuit went on to explain, one of the doctors who helped draft
a previous edition of WPATH’s Standards of Care testified that the Standards
of Care “is not a politically neutral document.”
Gibson
,
[18] As Justice Scalia explained, this line from Chief Justice Marshall has long
been misread to justify interpreting the Constitution in a way that is un-
moored from its text and history.
See
Antonin Scalia,
Essay: Assorted Canards
of Contemporary Legal Analysis
, 40 Case W. Res. L. Rev. 581, 594–96 (1989);
see
also Ogden
,
[19] Judge Rosenbaum also states that people are not truly “transgender” if they “experience some form of gender incongruence” but “ultimately embrace their birth-assigned gender or detransition.” Rosenbaum Dis. Op. at 59. But
[20] The following appendices are reproductions of written declarations submit- ted by Alabama.
[1] Incidentally, I note several inconsistencies in Judge Lagoa’s Statement. For one, the Statement discusses the facts and introduces new factual material. See Judge Lagoa’s Statement at 4–6, 29–31, 44, 48–49. We must respect the district court as the finder of fact. See Gonzalez v. Governor of Georgia , 978 F.3d 1266, 1270 (11th Cir. 2020). Neither the panel nor Judge Lagoa can reevaluate factual determinations or consider materials not before us, as the Statement does. See also Rosenbaum Dissent at 8 n.7. Further, I struggle with Judge La- goa’s discussion of medical findings, given her pronouncement that “[n]either an unelected district judge nor unelected circuit judge should resolve” policy questions informed by scientific, philosophical, and moral considerations. If this case presents policy questions that courts are ill-suited to resolve, a
[2]
See, e.g.
,
Price Waterhouse v. Hopkins
,
[3]
See Kadel v. Folwell
,
[1] That the district court and the panel in Bendiburg analyzed the case under the “shocks the conscience standard” is not surprising, as the full Eleventh Circuit had held just five years earlier that in the realm of abusive police (i.e.,
[2] I recognize that
Casey
has been overruled by
Dobbs v. Jackson Women’s Health
Org.
,
[3] One of the decisions
Lawrence
relied on was
Griswold v. Connecticut
, 381 U.S.
479 (1965).
See Lawrence
,
[4] Judge Lagoa, in her statement regarding the denial of rehearing en banc, adds a new and lengthy discussion of substantive due process in an attempt to de- fend the panel’s decision. The problem, of course, is that this new discussion is nowhere to be found in the panel opinion and does not constitute precedent. All we have in terms of binding law is the panel’s opinion, which is short on analysis and wrong in rationale.
[5] Given the strong language used by the Supreme Court, I do not understand how the panel here said that Parham “offers no support” for the parents’ sub- stantive due process claim. See Eknes-Tucker , 80 F.4th at 1223 (emphasis added).
[1] The district court relied on the following definition of “transgender”: “one
whose gender identity is different from the sex the person had or was identi-
fied as having at birth.”
Eknes-Tucker I
, 603 F. Supp. 3d at 1138 (citing
Transgender
, Merriam-Webster Unabr. Dictionary (3d ed. 2002)). We have
elaborated on the meaning of “transgender,” recognizing that a “transgender”
person “consistently, persistently, and insistently identifies as . . . a gender that
is different than the sex . . . assigned at birth.”
Adams ex rel. Kasper v. Sch. Bd.
of St. Johns Cnty.
,
[2] For ease of reference, I refer collectively to Plaintiffs as “Parents” when dis- cussing the Parents’ asserted due-process right and “Minors” when discussing the Minors’ asserted equal-protection right.
[3] These organizations included the American Academy of Pediatrics; the Ala- bama Chapter of the American Academy of Pediatrics; the Academic Pediatric Association; the American Academy of Child and Adolescent Psychiatry; the American Academy of Family Physicians; the American Academy of Nursing; the American Association of Physicians for Human Rights, Inc. d/b/a Health Professionals Advancing LGBTQ Equality; the American College of Obstetri- cians and Gynecologists; the American College of Osteopathic Pediatricians; the American College of Physicians; the American Medical Association; the American Pediatric Society; the American Psychiatric Association; the Associ- ation of American Medical Colleges; the Association of Medical School Pedi- atric Department Chairs; the Endocrine Society; the National Association of Pediatric Nurse Practitioners; the Pediatric Endocrine Society; the Society for Adolescent Health and Medicine; the Society for Pediatric Research; the Soci- ety of Pediatric Nurses; the Societies for Pediatric Urology; and the World Pro- fessional Association for Transgender Health. Eknes-Tucker I , 603 F. Supp. 3d at 1141 n.13.
[4] For ease of reference, I refer to Defendants collectively as “Alabama.”
[5] The Lagoa Statement maligns WPATH because, among other functions, WPATH advocates for transgender individuals. Lagoa St. at 30–31. But many healthcare professionals view an important part of their job as advocating for their community of patients. See Mark A. Earnest et al., Physician Advocacy: What Is It and How Do We Do It? , 85 Acad. Med. 63, 63 (2010) (noting “wide- spread acceptance of advocacy as a [medical] professional obligation”). That doesn’t mean they don’t also take the best possible care of their patients. And in the case of WPATH—“an international interdisciplinary, professional or- ganization”—its stated mission is “[t]o promote evidence based care, education, research , public policy, and respect in transgender health.” See World Prof. Ass’n for Transgender Health, Mission and Vision (last visited Aug. 19, 2024), https://www.wpath.org/about/mission-and-vision [https://perma.cc/KVJ3-WKDN] (emphases added). At least 22 major medi- cal organizations with the professionals, means, and motivation to evaluate
[8] Alabama also submitted eleven declarations. Of the declarations, three were from patients (Corinna Cohn (Appendix C to Lagoa Statement), Carol Freitas (Appendix B to Lagoa Statement), and KathyGrace Duncan (Appendix A to Lagoa Statement)). Freitas and Duncan were adults when they began transi- tioning medications, and Cohn was eighteen. None of the patients’ parents
[9] In contrast, the WPATH Standards of Care seek to ensure that the minor’s “mental health concerns (if any) that may interfere with diagnostic clarity, ca- pacity to consent, and gender-affirming medical treatments have been ad- dressed” before the minor begins to use transitioning medications. See E. Coleman et al., Standards of Care for the Health of Transgender and Gender Diverse People , Version 8 , I NT . J. T RANSGENDER H EALTH , Sept. 15, 2022, at S62 [herein- after WPATH Standards] [https://perma.cc/FQD7-YSFJ].
[10] The panel opinion itself does not cite
Abigail Alliance
, though it cites
L.W. ex
rel. Williams v. Skrmetti
,
[11] See Cleveland Clinic, Precocious Puberty/Early Puberty (last visited Aug. 19, 2024) https://my.clevelandclinic.org/health/diseases/21064-precocious- early-puberty [https://perma.cc/UM5B-BBTK].
[12] See , e.g. , U.S. Food & Drug Admin., Menopause: Medicines to Help You (Aug. 22, 2019), https://www.fda.gov/consumers/free-publications-women/men- opause-medicines-help-you [https://perma.cc/UKV5-U6UQ]; U.S. Food & Drug Admin., FDA Approves Weekly Therapy for Adult Growth Hormone Deficiency (Sept. 1, 2020), https://www.fda.gov/drugs/news-events-human-drugs/fda- approves-weekly-therapy-adult-growth-hormone-deficiency [https://perma.cc/75VU-T28M]. Besides these FDA-approved uses of hor- mones in adults, hormone therapies are widely prescribed and administered off-label for minors for intersex pubertal development and conditions such as gynecomastia (the overdevelopment or enlargement of the breast tissue in
[15] WPATH Standards, supra n.9, at S7.
[16] The Lagoa Statement justifies this mischaracterization by deflecting blame on the district court. See Lagoa St. at 11 (“[T]he panel opinion’s description of the right claimed here came directly from the district court . . . .”). But in context, the district court found that the Parents had a “fundamental right to
[17] In arguing that the state enjoys police powers to outlaw whatever medical treatments it wants that haven’t been shown to have “inform[ed] the meaning of the Fourteenth Amendment at the time it was ratified—July 9, 1868,” the Lagoa Statement proves our point. It relies on precedent that shows that a state’s police power isn’t plenary when it implicates a fundamental right. See Lagoa St. at 24–27. In Globe Newspaper Co. v. Superior Ct. for Norfolk Cnty. , 457 U.S. 596, 607–08 (1982), for instance, the Court recognized that States have a compelling interest in “safeguarding the physical and psychological well-being of a minor” but concluded that such an interest does not alone “justify a man- datory . . . rule.” Rather, when state police powers clash with a fundamental right, a “trial court can determine on a case-by-case basis whether” the state action “is necessary to protect the welfare of a minor victim.” Id. at 608. In other words, the state must establish a sufficient evidentiary record. Alabama did not do that here, and the panel opinion did not find that the district court clearly erred. The Lagoa Statement cannot engage in a do-over while denying en banc review.
[18] Williams Institute, UCLA School of Law, How Many Adults and Youth Identify as Transgender in the United States ? (June 2022), https://williamsinsti- tute.law.ucla.edu/publications/trans-adults-united-states/ [https://perma.cc/3SJF-KGWB].
[19] The Trevor Project, 2022 National Survey on LGBTQ Youth Mental Health by State 3 (2022), https://www.thetrevorproject.org/wp-content/up- loads/2022/12/The-Trevor-Project-2022-National-Survey-on-LGBTQ- Youth-Mental-Health-by-State.pdf [https://perma.cc/2UWR-NY25].
[20] For instance, the Lagoa Statement invokes a document called the WPATH Files “report,” which it characterizes as a whistleblower’s leak of several inter- nal documents impugning the credibility of the WPATH. Lagoa St. at 3–5, 30–31, 47–49. That document was prepared by an organization whose policy platform includes “Escape the Woke Matrix,” which, among other things,
[22] Plus, the parties and the district court might find other extra-record evi- dence more relevant and instructive. For instance, several studies have shown that transitioning medications have, in fact, improved the lives of many teens with gender dysphoria. More specifically, studies have repeatedly shown that gender-affirming hormone therapy markedly decreases suicidality and depres- sion among transgender minors who want such care. See, e.g. , Diana M. Tor- doff, et al., Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care , 5 JAMA Network Open 1, 6 (2022) (60% decrease in de- pression and 73% decrease in suicidality); Amy E. Green et al., Association of Gender-Affirming Hormone Therapy With Depression, Thoughts of Suicide, and At- tempted Suicide Among Transgender and Nonbinary Youth , 70 J. Adolescent Health 643, 647 (2022) (40% decrease in depression and suicidality); Jack L. Turban et al., Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation , 145 Pediatrics 1, 5–6 (2020) (statistically significant decrease in suicidal ideation); Luke Allen et al., Well-being and Suicidality Among Transgender Youth After Gen- der-affirming Hormones , 7 Clinical Practice in Pediatric Psychology 302, 306 (2019) (75% decrease in suicidality). Similarly, 98%—nearly all—of the over- 18-year-old respondents to the 2022 U.S. Transgender Survey who were receiv- ing transitioning medications at response time “reported that [the treatment] made them either ‘a lot more satisfied’ (84%) or ‘a little more satisfied’ (14%) with their life.” Sandy E. James et al., Early Insights: A Report of the 2022 U.S. Transgender Survey , at 18 (Feb. 2024), https://transequality.org/sites/de- fault/files/2024- 02/2022%20USTS%20Early%20Insights%20Report_FINAL.pdf [https://perma.cc/ZHW2-GAK7]. The 2022 U.S. Transgender Survey, which included 92,329 respondents (84,170 people 18 and older, and the remainder 16 or 17 years old), is the largest survey ever conducted of transgender indi- viduals in the United States. Id. at 4, 6. It’s not clear whether the survey asked 16- and 17-year-old respondents about their satisfaction with hormone treat- ment. But in any case, transitioning medications have been so beneficial for transgender individuals that 47% of Survey respondents considered moving to another state because their state’s government considered or passed legislation
[23] All Fifth Circuit decisions issued by the close of business on September 30, 1981, are binding precedent in this Court. Bonner v. City of Prichard , 661 F.2d 1206, 1207 (11th Cir. 1981) (en banc).
[24] Rex A. Hess, Estrogen in the Adult Male Reproductive Tract: A Review , 1:52 Re- productive Biology & Endocrinology 1, 1 (2003) (“Testosterone and estrogen are no longer considered male only and female only hormones. Both hor- mones are important in both sexes.”).
[25] This case is a far cry from those where the Court has recognized real, phys-
ical differences that survive intermediate scrutiny. In
Tuan Anh Nguyen v.
I.N.S.
,
[26] Applying Bostock and Brumby does not mean that prohibiting a particular medical treatment based on sex is automatically unconstitutional. As I’ve mentioned, if a state prohibited a course of treatment for transgender minors that was not medically accepted and that posed serious risks without benefits, that prohibition would likely survive even strict scrutiny. Of course, the Act does not impose that type of a prohibition. And even if we had such a law before us here, we still should have opted to correct the panel opinion’s peri- lous equal-protection analysis.
[27] See James et al., supra n.22, at 21–22. These numbers are roughly comparable to the 2015 Survey. See Sandy E. James et al., Nat’l Ctr. for Transgender Equal., The Report of the 2015 U.S. Transgender Survey , at 5, 13 (Dec. 2016), https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report- Dec17.pdf [https://perma.cc/5CL3-RG9E]. And while broad-scale quantita- tive data from prior periods may not exist, anecdotal evidence of discrimina- tion against transgender persons dates back to the Founding era and beyond. See, e.g. , Genny Beemyn, Transgender History in the United States , in Trans Bod- ies, Trans Selves (Laura Erickson-Schroth ed., Oxford Univ. Press 2022).
[28] More than 1.3 million transgender adults—roughly 0.5% of the adult popu- lation—live in the United States. See Williams Institute, supra n.18. Yet in 2022, only 45 elected officials—across all political levels in the country, includ- ing the local, state, and federal levels—identified as transgender. LGBTQ+ Victory Institute, Out for America 2022: A Census of LGBTQ Elected Officials Na- tionwide (Aug. 2022), https://victoryinstitute.org/out-for-america-2022/ [https://perma.cc/4WQM-D6W3]. And there is not (nor has there ever been) a single openly transgender judge on the federal bench. Lambda Legal, In a Record-Breaking Year for Judicial Nominations, the Biden Administration Fell Short on LGBTQ+ Representation (Feb. 1, 2022), https://lambdalegal.org/publica- tion/us_20230412_biden-admin-still-fell-short-on-lgbtq-representation-in-fed- eral-judicial-nominations/ [https://perma.cc/AFG9-7NBR].
[29] Since Alabama passed the Act, more than twenty other states have enacted legislation restricting the provision of gender-affirming hormone therapy and other procedures for transgender minors. See Arkansas S.B. 199 (2023); Florida S.B. 254 (2023); Georgia S.B. 140 (2023); Idaho H.B. 71 (2023); Indiana S.B. 480 (2023); Iowa S.F. 538 (2023); Kentucky S.B. 150 (2023); Louisiana H.B. 648 (2023); Mississippi H.B. 1125 (2023); Missouri S.B. 49 (2023); Montana S.B. 99 (2023); Nebraska L.B. 574 (2023); North Carolina H.B. 808 (2023); North Da- kota H.B. 1254 (2023); Ohio H.B. 68 (2024); Oklahoma S.B. 613 (2023); South Carolina H.B. 4624 (2024); South Dakota H.B. 1080 (2023); Tennessee S.B. 1 (2023); Texas S.B. 14 (2023); Utah S.B. 16 (2023); West Virginia H.B. 2007 (2023); Wyoming S.F. 0099 (2024).
[30] Nor is it at all relevant which law firms have “supported the Plaintiffs.” La- goa St. at 41. It is not our role to determine which law firms are “major” or “powerful.” And it is not the case that a group with (pro bono) legal represen- tation is not otherwise disenfranchised. To the contrary, many of the preemi- nent legal organizations in this country (e.g., the NAACP and ACLU) have dedicated themselves to representing minorities lacking in political power.
[31] See supra n.22.
